Cardiac sodium channel palmitoylation regulates channel function and cardiac excitability with implications for arrhythmia generation by Pei, Zifan
	  	  
CARDIAC	  SODIUM	  CHANNEL	  PALMITOYLATION	  REGULATES	  CHANNEL	  FUNCTION	  AND	  













Submitted	  to	  the	  faculty	  of	  the	  University	  Graduate	  School	  
in	  partial	  fulfillment	  of	  the	  requirements	  
for	  the	  degree	  
Doctor	  of	  Philosophy	  




	   ii	  
Accepted  by  the  Graduate  Faculty,  Indiana  University,  in  partial  





















         Andy  Hudmon,  Ph.D.  
  
December  09,  2016  
  
  





Patrick  L.  Sheets,  Ph.D.  
  
	   iii	  
Dedication  
This  work  is  dedicated  to  my  thesis  advisor,  Dr.  Theodore  R.  Cummins,  my  
parents,  Lin  Pei  and  Jieping  Miao  and  my  fiancé  Baichuan  Zhang.
	   iv	  
Acknowledgements
With  all  the  challenges,  joy  and  hardship  along  the  way,  the  journey  
through  Ph.D.  program  has  become  one  of  the  most  important  experience  in  my  
life.  Upon  finishing  my  dissertation,  I  would  like  to  take  the  time  to  thank  all  of  the  
individuals  that  have  inspired,  guided  and  supported  me  during  my  research.  I  
am  truly  grateful  that  they  have  influenced  me  in  all  aspects  and  have  
empowered  my  scientific  and  personal  growth.  My  dissertation  work  would  not  
have  been  completed  without  their  tremendous  help.    
First  and  foremost,  I  would  like  to  express  my  deepest  appreciation  to  Dr.  
Thedore  Cummins,  for  providing  me  the  great  opportunity  to  explore  the  current  
thesis  project.  Dr.  Cummins  taught  me  fundamentals  of  conducting  scientific  
research.  Under  his  guidance,  I  learned  how  to  address  research  problems,  
design  experiments  and  find  solutions  to  it.  He  also  inspired  me  by  his  
hardworking  and  his  passion  towards  scientific  research.  On  a  personal  level,  I  
deeply  appreciate  his  willingness  to  support  his  students  to  pursue  their  career  
goals.  Without  his  professional  guidance  and  persistent  help  this  dissertation  
would  not  have  been  possible.  
I  am  also  indebted  to  my  committee  members:  Dr.  Gerry  S.  Oxford,  Dr.  
Andy  Hudmon,  Dr.  Michael  Rubart-­von  der  Lohe  and  Dr.  Patrick  L.  Sheets.  They  
have  provided  precious  insights  and  assistance  for  my  dissertation  project.  
Specifically,  I  would  like  to  thank  Dr.  Gerry  S.  Oxford  for  providing  me  with  
significant  and  constructive  suggestions  during  my  research  and  defense.  And  I  
would  like  to  thank  Dr.  Michael  Rubart-­von  der  Lohe  for  numerous  helpful  
   v  
advices  and  inspiring  discussions  on  cardiac  electrophysiology.  Also,  I  would  like  
to  thank  Dr.  patrick  sheets  for  reading  the  dissertation  and  giving  me  insightful  
advice  during  my  writing  of  thesis.  Special  thanks  goes  to  Dr.  Andy  Hudmon,  who  
helped  me  develop  many  biochemistry  assays,  especially  for  his  generous  help  
during  the  tritium  labeling  experiments.  I  would  not  be  able  to  accomplish  this  
project  without  his  professional  assistance.  
Aside  from  my  committee,  I  would  like  to  thank  all  faculties  and  staffs  from  
the  department  of  Pharmacology  and  Toxicology  and  the  members  of  the  Stark  
Neurosciences  Research  Institute  for  all  the  guidance  and  support.  I  would  like  to  
acknowledge  Dr.  Jianting  Zhang,  Dr.Jill  C.  Fehrenbacher,  Dr.Rajesh  Khanna,  
Dr.Tao  Lu  for  their  advices  and  assistance  in  all  aspects  of  my  graduate  study.  
Additionally,  I  would  like  to  express  my  gratitude  to  all  the  colleagues  in  Cummins  
lab.  I  would  like  to  recognize  Dr.Yucheng  Xiao,  Dr.Zhiyong  Tan,  Dr.Cindy  
Barbosa,  Dr.Reesha  Patel,  James  Jackson,  Yanling  Pan,  Agnes  Zybura  and  
Emily  Mason,  for  all  their  help  during  my  graduate  studies.  Special  thanks  goes  
to  Dr.  Yucheng  Xiao  for  his  endless  help  during  my  first  two  years  in  the  lab.  He  
is  always  willing  to  take  time  to  teach  me  experimental  techniques  and  lab  
practices.  I  deeply  appreciate  his  patience  and  help.    
I  would  also  like  to  thank  members  from  hudmon  lab,  for  the  continuous  
help  for  my  biochemistry  experiments.  Especially  Dr.  Jingwei  Meng,  he  has  spent  
a  lot  of  time  helping  me  develop  the  biochemistry  assays  and  trouble  shotting.    
Apart  from  my  academic  life,  I  would  also  extend  my  deep  appreciation  to  my  
family  for  their  unconditional  love,  care  and  support.  I  would  like  to  thank  my  
   vi  
parents  for  their  continuous  encouragement  and  support.  It  is  because  of  the  
passion,  diligence  and  dedication  learned  from  them  that  motived  and  
empowered  me  to  achieve  the  current  accomplishments.  I  would  also  like  to  
thank  my  fiancé  Baichuan  Zhang,  for  this  accompany  and  endless  support,  which  






   vii  
Zifan  Pei  
  
Cardiac	  sodium	  channel	  palmitoylation	  regulates	  channel	  function	  and	  cardiac	  
excitability	  with	  implications	  for	  arrhythmia	  generation	  
  
  
The  cardiac  voltage-­gated  sodium  channels  (Nav1.5)  play  a  specific  and  
critical  role  in  regulating  cardiac  electrical  activity  by  initiating  and  propagating  
action  potentials  in  the  heart.  The  association  between  Nav1.5  dysfunctions  and  
generation  of  various  types  of  cardiac  arrhythmia  disease,  including  long-­QT3  
and  Brugada  syndrome,  is  well  established.  Many  types  of  post-­translational  
modifications  have  been  shown  to  regulate  Nav1.5  biophysical  properties,  
including  phosphorylation,  glycosylation  and  ubiquitination.  However,  our  
understanding  about  how  post-­translational  lipid  modification  affects  sodium  
channel  function  and  cellular  excitability,  is  still  lacking.  The  goal  of  this  
dissertation  is  to  characterize  Nav1.5  palmitoylation,  one  of  the  most  common  
post-­translational  lipid  modification  and  its  role  in  regulating  Nav1.5  function  and  
cardiac  excitability.    
In  our  studies,  three  lines  of  biochemistry  evidence  were  shown  to  confirm  
Nav1.5  palmitoylation  in  both  native  expression  background  and  heterologous  
expression  system.  Moreover,  palmitoylation  of  Nav1.5  can  be  bidirectionally  
regulated  using  2-­Br-­palmitate  and  palmitic  acid.  Our  results  also  demonstrated  
that  enhanced  palmitoylation  in  both  cardiomyocytes  and  HEK293  cells  
increases  sodium  channel  availability  and  late  sodium  current  activity,  leading  to  
enhanced  cardiac  excitability  and  prolonged  action  potential  duration.  In  contrast,  
blocking  palmitoylation  by  2-­Br-­palmitiate  increases  closed-­state  channel  
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inactivation  and  reduces  myocyte  excitability.  Our  computer  simulation  results  
confirmed  that  the  observed  modification  in  Nav1.5  gating  properties  by  protein  
palmitoylation  are  adequate  for  the  alterations  in  cardiac  excitability.  Mutations  of  
potential  palmitoylation  sites  predicted  by  CSS-­Palm  bioinformatics  tool  were  
introduced  into  wild-­type  Nav1.5  constructs  using  site-­directed  mutagenesis.  
Further  studies  revealed  four  cysteines  (C981,  C1176,  C1178,  C1179)  as  
possible  Nav1.5  palmitoylation  sites.  In  particular,  a  mutation  of  one  of  these  
sites(C981)  is  associated  with  cardiac  arrhythmia  disease.  Cysteine  to  
phenylalanine  mutation  at  this  site  largely  enhances  of  channel  closed-­state  
inactivation  and  ablates  sensitivity  to  depalmitoylation.  Therefore,  C981  might  be  
the  most  important  site  that  regulates  Nav1.5  palmitoylation.  In  summary,  this  
dissertation  research  identified  novel  post-­translational  modification  on  Nav1.5  
and  revealed  important  details  behind  this  process.  Our  data  provides  new  
insights  on  how  post-­translational  lipid  modification  alters  cardiomyocyte  
excitability  and  its  potential  role  in  arrhythmogenesis.    
  
Theodore  R.  Cummins,  Ph.D.,  Chair
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I.   INTRODUCTION  
A.     Overview  of  the  thesis  project  
Cardiac  voltage-­gated  sodium  channels  (Nav1.5),  a  voltage-­gate  sodium  
channel  subtype  that  is  mainly  expressed  in  cardiac  tissues,  play  an  essential  
role  in  regulating  cardiac  electric  activity  by  initiating  and  propagating  action  
potentials  in  the  heart.  Altered  Nav1.5  function  is  associated  with  multiple  cardiac  
diseases  including  LQT3  and  Brugada  syndrome.  Many  studies  have  
investigated  the  underlying  mechanism  of  how  Nav1.5  dysfunction  leads  to  
cardiac  arrhythmia  diseases.    
Mechanistically,  LQT3  disease  is  associated  with  Nav1.5  gain-­of-­function  
mutation  with  a  constant  and  enhanced  entry  of  Na+,  while  most  clinical  cases  of  
Brugada  syndrome  reflect  a  loss  of  function  of  Nav1.5,  associated  with  
decreased  expression  level  or  enhanced  channel  inactivation  (Moric,  Herbert  et  
al.  2003).  Previous  studies  indicate  that  Nav1.5  polymorphisms  can  induce  direct  
changes  to  the  channel  biophysical  properties  and  lead  to  LQT3  or  Brugada  
syndrome.  It  is  clear  that  genetic  background  plays  a  critical  role  in  regulating  
Nav1.5  protein  expression  and  function;;  many  studies  have  also  revealed  that  
post-­translational  modifications  of  Nav1.5  contribute  to  altered  channel  function  
under  physiological  and  pathological  conditions.  Nav1.5  is  subject  to  various  
post-­translational  modifications.  Among  them,  Nav1.5  phosphorylation,  
ubiquitination  and  glycosylation  have  been  extensively  studied.  Their  roles  in  
cardiac  diseases  and  specific  sites  of  post-­translational  modification  have  been  
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revealed.  However,  our  understanding  of  Nav1.5  regulation  by  lipid  modifications  
is  still  lacking.    
In  this  project,  we  demonstrate  that  Nav1.5  is  subject  to  palmitoylation,  a  
reversible  post-­translational  lipid  modification.  Nav1.5  palmitoylation  was  found  in  
both  a  heterologous  expression  system  and  cardiac  tissues.  In  cardiomyocytes,  
palmitoylation  increases  channel  availability  and  late  sodium  current  activity,  
leading  to  enhanced  cardiac  excitability  and  prolonged  action  potential  duration.  
In  contrast,  blocking  palmitoylation  substantially  hyperpolarized  voltage-­
dependence  of  inactivation  and  abolished  cardiomyocyte  excitability.  Our  
computer  simulations  suggest  that  these  alterations  of  Nav1.5  function  alone  are  
sufficient  to  induce  the  changes  found  in  cardiac  action  potentials,  such  as  the  
shifted  voltage-­dependence  of  inactivation  and  altered  persistent  current.  
Clinically,  these  changes  could  potentially  lead  to  Long  QT  syndrome  or  Brugada  
syndrome.    
We  also  identify  four  cysteines  as  possible  Nav1.5  palmitoylation  
substrates  and  mutagenesis  of  all  four  cysteines  mimics  the  effect  of  
palmitoylation  inhibition.  Moreover,  a  mutation  of  one  of  these  cysteines  
associated  with  cardiac  arrhythmia  (C981F),  induces  a  significant  enhancement  
of  channel  closed-­state  inactivation  and  ablates  sensitivity  to  depalmitoylation.  
Our  data  indicate  that  alterations  in  palmitoylation  can  substantially  control  
Nav1.5  function  and  cardiac  excitability  and  this  form  of  post-­translational  
modification  is  likely  an  important  contributor  to  acquired  and  congenital  
arrhythmias.  
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      In  summary,  our  experimental  data  and  computer  simulations  suggest  that  
palmitoylation  not  only  has  profound  impact  on  Nav1.5  activity  and  cardiac  
excitability,  but  is  also  likely  to  play  a  previously  unrecognized  role  in  both  
inherited  and  acquired  cardiac  channelopathies.  This  project  presents  novel  
mechanism  underlying  cardiac  arrhythmias  and  may  represent  a  new  target  in  
treating  cardiac  diseases.	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B.   Brief  overview  of  ion  channels  and  history  of  discovering  membrane  
excitation  
Cell  membrane  forms  the  boundary  of  the  cell  and  separates  cells  from  
exterior  environment.  The  lipid  bilayer  of  biological  membranes  has  selected  
permeability  to  different  molecules  (ions  and  polar  molecules),  controlling  the  
flow  of  substance  across  the  membrane.  There  are  different  types  of  membrane  
transport  proteins  that  determine  the  permeability  of  the  membrane.  Among  
them,  active  transporters  facilitate  an  ‘active’  transport  of  molecules  (usually  
against  their  concentration  gradient)  using  cellular  energy.  Passive  transporters,  
(e.g.  ion  channels),  on  the  other  hand,  allow  the  ‘passive’  diffusion  of  molecules  
(usually  in  the  same  direction  as  the  concentration  or  electrochemical  gradient)  
without  energy  assumption.      
Ion  channels,  pore-­forming  integral  membrane  proteins  gate  the  flow  of  
ions  across  the  cell  membrane  and  therefore,  contribute  to  control  the  cell  resting  
membrane  potential  and  regulate  cell  excitability.  Two  Nobel  prize  winning  
physiologists,  Sir  Alan  L.  Hodgkin  and  Sir  Andrew  F.  Huxley,  first  discovered  the  
ionic  mechanism  underlying  action  potential  generation  using  the  squid  giant  
axon(Hodgkin  and  Huxley  1952).  These  landmark  experiments  demonstrated  
that  the  transmembrane  sodium  and  potassium  currents  were  responsible  for  the  
generation  of  the  action  potential.  Moreover,  they  were  able  to  identify  the  
influence  of  membrane  potential  on  sodium  current  kinetics  and  quantitatively  
describe  the  sodium  conductance  and  gating  mechanism.  This  work  provides  the  
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foundation  of  understanding  action  potential  generation  and  propagation  and  
paves  the  way  for  later  ion  channel  studies.    
After  Hodgkin  and  Huxley  identified  the  voltage  dependent  gating  of  ion  
channels  using  the  voltage  clamp  technique,  this  technique  became  widely  used  
to  study  voltage  gated  ion  channels.  In  1964,  a  paralytic  neurotoxin  called  
tetrodotoxin  (TTX)  was  discovered  by  Toshio  Narahashi  and  John  W.  Moore  
(Mosher,  Fuhrman  et  al.  1964,  Narahashi,  Moore  et  al.  1964,  Scheuer  1970).  
TTX  was  found  in  the  liver  of  the  puffer  fish  and  was  revealed  to  have  selective  
blockage  for  sodium  ion  flow  across  the  membrane,  indicating  the  existence  of  a  
specific  pathway  for  sodium  ion  conductance  (Narahashi,  Moore  et  al.  1964).  
Several  years  later,  Hille  discovered  that  saxitoxin,  a  shellfish  toxin,  was  another  
distinct  blocker  of  sodium  current  while  studying  the  voltage-­gated  ion  channels  
from  frog  neuron  (Hille  1968).  By  comparing  the  mobility  of  different  cations,  he  
was  also  able  to  obtain  more  insight  into  sodium  channel  structure  and  ion  
selectivity.  He  described  the  pore  region  of  the  sodium  channel  as  a  filter  that  
controls  the  ion  selectivity.  Besides,  he  also  suggested  that  the  non-­covalent  
bond  (hydrogen  bond)  between  ions  and  channels  must  be  present  to  allow  the  
flow  of  ions  through  the  putative  selectivity  pore  (Hille  1971).  These  findings  led  
to  the  identification  and  understanding  of  sodium  channel  protein.  Now,  our  
knowledge  of  sodium  channel  proteins  and  mechanisms  underlying  membrane  
excitability  have  progressed  significantly  since  those  days.  As  the  result  of  the  
rapid  development  of  patch  clamp  and  other  advanced  techniques,  we  now  have  
a  clearer  understanding  of  sodium  channel  structure,  kinetics,  function  and  
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modulation.  As  this  dissertation  focuses  primarily  on  voltage-­gated  sodium  
channel  post  translational  modification,  it  is  important  to  briefly  introduce  the  
structure  and  function  voltage-­gated  sodium  channels.  
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C.   Voltage-­gated  sodium  channels  
Voltage-­gated  sodium  channels  (VGSCs)  are  integral  membrane  protein  
complexes  that  allow  sodium  ion  flow  across  the  membrane  and  conduct  
transmembrane  sodium  currents(Goldin  2001).  VGSCs  consist  of  the  pore  
forming  α  subunit  and  one  or  more  β  auxiliary  subunits  that  regulate  functions  of  
channels  (Catterall,  Goldin  et  al.  2005).  The  sodium  channel  α  subunit  consists  of  
four  transmembrane  domains  (DI-­DIV),  with  each  containing  six  transmembrane  
segments  (S1-­S6,  Figure  1).  Segments  1,  2,  3  and  4  serve  as  voltage  sensor  and  
change  confirmations  in  response  to  membrane  potential  change.  Segments  5  
and  6  form  the  pore  of  the  channel  and  this  is  responsible  for  ion  conduction  
through  the  channel(Yellen  1998).  Altogether,  12  transmembrane  segments  in  
the  α  subunit  form  a  complex  pore  like  structure  in  the  plasma  membrane  (Figure  
2)  and  this  subunit  has  a  molecular  weight  of  about  220-­260  kD(Levinson  and  
Ellory  1973,  Catterall,  Goldin  et  al.  2005,  Payandeh,  Scheuer  et  al.  2011).    
VGSCs  have  three  basic  configurations:  resting(closed),  activated  (open),  
and  inactivated  (Figure  3a).  Under  resting  membrane  potential,  the  cell  
membrane  potential  is  at  negative  hyperpolarized  voltages  and  the  VGSCs  
activate(open)  in  response  to  the  membrane  potential  depolarization.  When  
membrane  depolarization  begins,  several  positively  charged  residues  on  the  S4  
segments  are  able  to  sense  the  membrane  potential  change,  and  this  leads  to  
outward  movement  of  S4  segments,  initiating  the  conformational  change  of  
VGSCs  (Figure  3b)  (Catterall  2000).  The  channel  is  then  in  transition  to  
activated(open)  configuration,  providing  a  conduction  pathway  for  the  sodium  
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currents  through  the  channel  pore(Stuhmer,  Conti  et  al.  1989).  Very  soon  after  
channel  activation  (usually  within  milliseconds),  the  inactivation  gate  that  tethered  
to  the  sodium  channel  protein  will  block  the  channel  and  prevent  sodium  
conductance(Goldin  2003).  VGSCs  transition  to  a  non-­conducting,  inactivated  
conformation.  This  process  is  often  referred  to  as  ‘fast  inactivation’.  Structure  
function  studies  revealed  that  the  IFM  motif  (located  in  the  intracellular  linker  of  
DIII  and  DIV)  with  three  hydrophobic  amino  acids  Isoleucine,  Phenylalanine,  and  
Methionine  are  largely  responsible  for  the  channel  fast  inactivation(West,  Patton  
et  al.  1992).  There  is  also  another  type  of  inactivation  that  develops  in  response  
to  longer  depolarization  time  periods  (usually  hundreds  of  milliseconds)  called  
‘slow  inactivation’(Silva  2014).  Slow  inactivation  will  sustain  for  a  few  seconds  or  
even  tens  of  seconds  and  is  associated  with  altered  excitability  in  neurons  and  
myocytes,  leading  to  various  disease  phenotypes  such  as  hyperkalemic  periodic  
paralysis  and  long-­QT  syndrome(Vilin  and  Ruben  2001).  However,  the  detailed  
molecular  mechanism  of  slow  inactivation  is  still  unknown(Ulbricht  2005).  Once  
VGSCs  enter  an  inactivated  configuration,  the  channels  are  refractory  to  future  
stimuli  and  will  not  be  able  to  open  again  until  the  membrane  potential  has  
repolarized  to  negative  potentials.  This  process  is  called  ‘recovery  from  
inactivation’.  It  prevents  the  cells  from  premature  re-­excitation  and  is  critical  in  
regulating  action  potential  firing  in  excitable  cells.  Altered  recovery  rate  may  
contribute  to  a  disrupted  action  potential  generation  pattern.  Previous  study  on  
skeletal  muscle  sodium  channel  reveals  that  defective  recovery  from  fast  
inactivation  may  lead  to  disease  phenotype  producing  myotonic  
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discharges(Richmond,  VanDeCarr  et  al.  1997).  Once  sodium  channel  is  fully  
recovered  from  inactivation,  it  will  restore  to  the  original  state  and  regain  their  
ability  to  open  upon  the  next  stimulus.      
The  voltage-­gated  sodium  channel  family  consists  of  9  members  and  they  
share  more  than  50%  common  amino  acid  sequence  in  transmembrane  
segments  and  extracellular  domains(Yu  and  Catterall  2003).  However,  they  are  
found  to  be  expressed  in  a  variety  of  tissues  and  have  distinct  biophysical  
properties.    For  example,  Nav1.4  is  predominantly  expressed  in  skeletal  muscle  
cells  and  its  mutation  is  associated  with  myotonia  and  periodic  
paralysis(Loussouarn,  Sternberg  et  al.  2015).  Nav1.8  and  Nav1.9  show  a  much  
slower  rate  of  inactivation  compared  to  other  subtypes  of  VGSCs(Cummins  and  
Waxman  1997).  Based  on  the  sensitivity  to  tetrodotoxin(TTX),  VGSCs  can  be  
divided  into  two  groups:  TTX  sensitive  VGSCs(Nav1.1,  Nav1.2,  Nav1.3,  Nav1.4,  
Nav1.6,  Nav1.7)  and  TTX  resistant  VGSCs(Nav1.5,  Nav1.8,  Nav1.9).  Table  1  
summarizes  the  properties  of  9  subtypes  of  sodium  channels  and  their  disease  
associations.  
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Figure  1.  Schematic  representation  of  the  linear  structure  of  α  subunit  for  voltage-­
gated  sodium  channels  (VGSCs).  The  α  subunit  consists  of  four  homologous  
transmembrane  domains(DI-­DIV).  Each  domain  contains  six  transmembrane  
segments  (S1-­S6).  Among  all,  S1-­S4  serve  as  the  voltage  sensor  of  the  channel  
and  S5-­S6  segments  form  the  pore.  The  IFM  inactivation  particle  is  located  in  
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Figure  2.  Simplified  scheme  of  three-­dimensional  arrangement  of  sodium  
channel  α  subunit.  Four  homologous  domains  (DI  -­  DIV)  are  folded  together  and  
they  form  a  pore  like  structure.  Each  domain  contains  six  transmembrane  
segments  (S1-­S6).  IFM  motif  locates  in  the  DIII  to  DIV  intracellular  linker  and  
forms  the  inactivation  gate.  In  the  top  view,  the  P-­loops  connecting  the  S5  and  
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Figure  3.  Schematic  representation  of  three  states  of  voltage-­gated  sodium  
channels.  A.  Diagram  showing  the  proposed  scheme  for  voltage-­gated  sodium  
channels  transitions  from  resting  state  to  activated  and  inactivated  state.  Sodium  
channels  are  closed  at  resting  state  and  change  open  configuration  open  
activation.  IFM  inactivation  gate  blocks  the  channel  during  inactivation  state,  
preventing  Na+  flow  into  the  cell.  B.  A  simplified  scheme  showing  the  movement  
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Table  1.  Sodium  channel  subtypes  and  associated  disease  phenotypes  






Expression   Channelopathies  
Nav1.1   SCN1A   2q24   5-­10   CNS,PNS   Epilepsy,  Pain  
Nav1.2   SCN2A   2q24.3   10   CNS,PNS   Epilepsy  
Nav1.3   SCN3A   2q24   2-­15   CNS,PNS   Epilepsy,  Pain  











Nav1.6   SCN8A   12q13   1   CNS,PNS   Epilepsy,  Pain  
Nav1.7   SCN9A   2q24   4   PNS   Pain  
Nav1.8   SCN10A   3p22.2   >50,000   PNS   Pain  
Nav1.9   SCN11A   3p22.2   40000   PNS   Pain  
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D.   Cardiac  sodium  channels  and  its  role  in  cardiac  excitability  
Voltage-­gated  sodium  channels  (VGSCs)  are  responsible  for  initiation  and  
propagation  of  action  potentials  in  excitable  cells  (e.g.,  neurons,  muscles,  
myocytes)  (Hodgkin  and  Huxley  1952,  Agnew  1984,  Catterall  2000).  The  cardiac  
subtype  Nav1.5  is  predominantly  expressed  in  the  heart  and  plays  an  essential  
role  in  regulating  cardiac  electric  activity(Rogart,  Cribbs  et  al.  1989).    
The  resting  membrane  potential  of  cardiomyocytes  is  usually  maintained  
at  -­80  to  -­90mV(Grant  2009).  This  potential  is  determined  by  the  selective  
permeability  of  the  cell  membrane  to  different  ions  and  the  activities  of  ion  pumps  
like  Na+-­K+-­ATPase.  This  resting  stage  is  also  referred  to  as  phase  ‘4’  in  a  
cardiac  action  potential  (Figure  4).  The  VGSCs  remain  closed  at  resting  
membrane  potential.  Once  changes  in  transmembrane  potential  are  detected  by  
voltage  sensor  domain,  the  outward  movement  of  voltage  sensor  will  be  
triggered.  VGSCs  will  then  change  conformation  to  an  activated  conducting  
configuration.  Sodium  ions  then  flow  (down  their  concentration  gradient)  into  the  
cell,  leading  to  further  membrane  depolarization.  VGSCs  activation  lasts  for  a  few  
milliseconds  and  is  responsible  for  the  rapid  depolarization  phase  of  an  action  
potential  (phase  ‘0’  of  the  action  potential)(Carmeliet  2002,  Ulbricht  2005).  The  
buildup  of  positive  charges  inside  of  the  membrane  causes  VGSCs  to  inactivate  
and  then  transition  to  a  closed  conformation.  At  the  same  time,  the  change  in  
membrane  potential  leads  to  the  opening  of  voltage-­gated  potassium  channels.  
The  rapid  outflow  of  positively  charged  K+  ions  slightly  lower  the  membrane  
potential  and  constitute  the  repolarization  phase  (phase  ‘1’)  of  the  action  
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potential.  Then,  the  activation  of  voltage-­gated  calcium  channels  and  delayed  
rectifier  potassium  channels  maintain  a  plateau  phase  (phase  ‘2’)  of  the  action  
potential(Kenyon  and  Sutko  1987).  Then  L-­type  Ca2+  channels  inactivate  and  
many  potassium  channels  remain  open  (primarily  the  rapid  delayed  rectifier  K+  
channels  (IKr)  and  the  inwardly  rectifying  K+  current,  IK1),  resulting  in  a  rapid  
repolarization  phase  (phase  ‘3’)  of  the  action  potential.
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Figure  4.  Illustration  of  single  cardiac  action  potential  and  its  corresponding  ion  
conductance  in  different  phases.  Top  panel  depicts  standard  cardiac  action  
potential  waveform  and  1-­4  indicate  four  phases  in  cardiac  action  potential.  
Lower  panel  indicates  the  corresponding  ion  conductance  participating  in  each  
phase  of  the  action  potential.  Sodium  current  is  primarily  involved  in  phase  0  of  
the  action  potential  in  the  ventricular  cardiomyocyte.  Potassium  currents  
participates  in  phase  1,2  and  3  in  cardiac  action  potential.  Calcium  current  is  
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E.   ECG  and  cardiac  action  potential  
Electrocardiogram  (ECG)  is  a  measurement  of  the  electrical  activity  of  the  
beating  heart  (Kligfield,  Gettes  et  al.  2007).  Clinically,  ECG  is  widely  used  to  
determine  the  risk  factors  of  cardiac  arrhythmia.  Figure  5  summarizes  the  cardiac  
action  potential  and  corresponding  ECG.  The  P  wave  indicates  the  atrial  
depolarization,  which  spreads  from  the  sinoatrial  (SA)  node  towards  the  
atrioventricular  (AV)  node,  and  from  the  right  atrium  to  the  left  atrium.  P  wave  has  
a  duration  around  80ms.  The  QRS  complex  represents  the  rapid  depolarization  
of  the  ventricles  and  has  a  duration  between  80  to  100ms.  Following  the  QRS  
complex,  there  is  a  ST  segment  connecting  QRS  complex  and  the  T  wave.  The  
ST  segment  indicates  the  period  when  the  ventricles  are  depolarized  and  the  
length  of  the  ST  segment  is  associated  with  the  plateau  phase  of  the  action  
potential.  The  following  T  wave  indicates  the  ventricular  repolarization  and  
normally  has  a  longer  duration  compared  with  the  depolarization  phase.  
Therefore,  the  total  QT  interval,	  measured  from  the  beginning  of  the  QRS  
complex  to  the  end  of  the  T  wave,  represents  ventricular  depolarization  and  
repolarization  and  can  be  used  to  estimate  the  average  action  potential  
duration(Rautaharju,  Surawicz  et  al.  2009).  QT  interval  ranges  can  vary  with  
heart  rate,  therefore,  a  corrected  QT  interval  (QT  interval  dividing  by  the  square  
root  of  the  RR  interval,  refered  to  as  ‘QTc’)  is  often  used  to  study  the  range  of  QT  
interval  (Jackman,  Friday  et  al.  1988,  Funck-­Brentano  and  Jaillon  1993).  The  QT  
interval  is  usually  within  the  range  from  350  ms  to  440  ms(Levine,  Rosero  et  al.  
2008).  However,  it  can  be  longer  under  pathological  conditions  (Morita,  Wu  et  al.  
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2008).  In  clinical  cases,  a  prolonged  QT  interval  (>  440  ms)  is  often  used  as  an  
important  parameter  to  diagnose  or  predict  potential  risk  of  cardiac  arrhythmia  
generation(Schwartz  1985).  
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Figure  5.  Ventricular  action  potential  and  its  relationship  with  the  ECG  study.  The  
top  panel  shows  a  standard  single  cardiac  ventricular  action  potential  wave  form.  
The  lower  panel  depicts  a  corresponding  ECG  trace.  The  QRS  complex  
represents  the  rapid  depolarization  phase  (phase  ‘0’)  of  the  action  potential,  and  
the  T-­wave  represents  the  repolarization  phase  (phase  ‘3’)  of  the  action  potential.  
The  QT-­interval  (from  the  starting  point  of  the  Q  wave  to  the  end  point  of  the  T-­
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F.   The  role  of  cardiac  sodium  channels  in  the  genesis  of  cardiac  
arrhythmias  
As  described  previously,  cardiac  sodium  channels  regulate  the  sodium  
conductance  during  the  rapid  upstroke  phase  (phase  0)  of  the  cardiac  action  
potential  and  rapidly  inactivate  after  opening.  Alterations  of  Nav1.5  functions  may  
contribute  significantly  to  various  kinds  of  cardiac  arrhythmia  diseases.  Nav1.5  
abnormalities  are  typically  caused  by  mutations  in  genes  encoding  cardiac  
sodium  channels  (SCN5A)  or  its  accessory  proteins  (Song  and  Shou  2012).    
A  large  number  of  studies  focus  on  the  effects  of  SCN5A  mutations  on  the  
normal  molecular  structure  and  function  activities  of  Nav1.5,  and  how  that  leads  
to  arrhymogenic  diseases.  Previous  studies  demonstrate  that  altered  Nav1.5  
function  may  induce  many  different  types  of  cardiac  arrhythmia  diseases,
including  long  QT  syndrome  type  3  (LQT-­3),  Brugada  syndrome,  cardiac  
conduction  defect,  atrial  fibrillation,  dilated  cardiomyopathy  or  overlapping  
syndromes  (Ruan,  Liu  et  al.  2009).  Among  them,  LQT-­3  and  Brugada  syndrome  
are  most  common  arrhythmia  phenotypes  that  connect  with  Nav1.5  malfunctions.    
Long  QT  syndrome  is  an  inherited  or  acquired  cardiac  abnormality  with  
delayed  repolarization  of  the  heart,  which  increases  the  risk  of  sudden  death  due  
to  ventricular  arrhythmia.  It  is  often  characterized  by  prolonged  QT  interval  on  
electrocardiogram  (Schwartz  2012).  Prolonged  QT  interval  is  generated  by  
increased  action  potential  duration  and  delayed  ventricular  repolarization  (Figure  
7).  Long-­QT  syndrome  (LQTS)  can  be  generated  from  mutation  of  several  genes  
encoding  a  protein  that  is  involved  in  ventricular  repolarization.  Based  on  which  
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gene  mutation  leads  to  LQT  phenotype,  LQTS  is  classified  into  different  subtypes  
(Table  2).  LQT-­3  is  specifically  associated  with  mutations  in  SCN5A,  the  gene  
encoding  cardiac  sodium  channels.    
Many  SCN5A  mutations  have  been  identified  and  characterized  in  patients  
with  LQT-­3  phenotype.  Most  mutations  are  sodium  channel  gain-­of-­function  
mutations(Wang,  Shen  et  al.  1995).  The  most  commonly  studied  mechanism  is  
the  sodium  channel  fast  inactivation  defect,  which  leads  to  a  non-­inactivating  
persistent  (late)  sodium  channel  current  (Figure  8).  Even  though  persistent  
current  amplitude  is  rather  small  compared  to  peak  current  (usually  less  than  
1%),  it  significantly  contributes  to  delayed  repolarization  of  cardiac  action  
potential  and  further  leads  to  a  prolonged  action  potential  duration  and  QT  
interval  (Bennett,  Yazawa  et  al.  1995).    
Another  commonly  occurring  mechanism  of  SCN5A  mutation  to  cause  
LQT-­3  is  the  increased  window  current  (Wang,  Yazawa  et  al.  1996).  In  general,  
more  than  99%  of  Nav1.5  are  inactivated  by  the  end  of  action  potential  phase  1  
and  are  in  a  refractory  period  until  fully  recovered  from  inactivation  during  phase  
4.  Only  a  small  portion  of  sodium  channels  (usually  less  than  1%)  can  activate  
during  phase  3,  when  cells  are  at  voltages  depolarized  enough  to  activate  a  
small  fraction  of  channels  but  not  enough  to  fully  inactivate  all  the  channels.  The  
overlap  between  voltage  dependence  of  activation  and  inactivation  curves  
reflects  this  window  (overlap)  of  membrane  potential  under  which  a  small  fraction  
of  sodium  channel  can  be  activated  but  not  inactivated.  Therefore,  these  small  
fraction  of  sodium  currents  are  often  referred  to  as  ‘window  currents’  (Figure  6).  
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The  voltage  range  of  the  window  current  is  generally  very  small  under  
physiological  condition  and  hence  will  not  affect  action  potential  generation  
significantly.  However,  under  pathological  condition,  i.e.  delayed  inactivation  
(inactivation  shifted  to  more  depolarized  potentials),  the  voltage  range  will  
become  wider,  leading  to  an  increased  window  current  during  action  potential  
phase  3  and  contribute  to  cardiac  arrhythmia  generation  (Wedekind,  Smits  et  al.  
2001).  Apart  from  the  above  mentioned  two  mechanisms,  other  less  common  
mechanisms  have  also  been  revealed,  including  an  enhanced  peak  sodium  
current  density  (Rivolta,  Abriel  et  al.  2001),  slower  inactivation  (Ruan,  Liu  et  al.  
2007),  and  faster  recovery  from  inactivation  (Clancy,  Tateyama  et  al.  2003).    
Brugada  syndrome  is  another  arrhythmia  phenotype  that  can  be  caused  
by  SCN5A  mutation.  There  are  6  common  types  of  Brugada  syndromes  and  type  
I  is  associated  with  Nav1.5  malfunction  (Table  3).  Unlike  LQT-­3,  Brugada  
syndrome  patients  generally  have  a  SCN5A  loss-­of-­function  mutation.  One  of  the  
common  molecular  mechanisms  of  Brugada  syndrome  is  the  decreased  sodium  
peak  current,  which  can  result  from  a  decreased  surface  expression  of  sodium  
channels(Mohler,  Rivolta  et  al.  2004),  trafficking  defect  or  defect  of  interaction  
with  accessory  subunits  (Valdivia,  Tester  et  al.  2004).  Another  mechanism  
involves  the  alteration  in  sodium  channel  gating  properties,  including  delayed  
activation  (Smits,  Koopmann  et  al.  2005)  or  enhanced  inactivation(Bezzina,  
Veldkamp  et  al.  1999,  Dumaine,  Towbin  et  al.  1999).  Therefore,  loss-­of-­function  
mutations  in  SCN5A  of  will  reduce  the  probability  of  channel  opening  and  
significantly  decrease  the  sodium  inflow,  which  further  leads  to  a  shortened  
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action  potential  duration  and  the  loss  of  action  potential  dome  (caused  by  
transmural  repolarization  gradients,  Figure  9A).  This  is  often  reflected  in  patients  
ECG  as  ST  segment  elevation  and  occurrence  of  arrhythmias  (Figure  9B).    
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Figure  6.  Voltage  dependence  of  activation  and  inactivation  of  cardiac  sodium  
channel.  A.  Representative  curve  of  cardiac  sodium  channel  voltage  dependence  
of  activation.  50ms  depolarizing  voltage  steps  was  applied  from  a  holding  
potential  of  -­100  mV.    The  activation  curve  was  plotted  by  normalized  
conductance  versus  membrane  potential,  indicating  fraction  of  channels  
activated  under  different  voltage.  B.  Representative  curve  of  sodium  channel  
voltage  dependence  of  inactivation.  500ms  prepulse  was  applied  from  -­170  to  -­
20  to  inactivate  the  channels.  Then,  the  fraction  of  channels  remain  active  was  
measured  by  a  test  pulse  at  -­10mV.  The  inactivation  curve  was  plotted  by  
normalized  current  versus  membrane  potential,  indicating  the  fraction  of  
channels  inactivated.  C,  D.  Representative  window  current  (grey  area).  The  
window  current  was  generated  under  the  voltage  that  depolarized  enough  to  
activate  sodium  channels  but  not  sufficient  to  fully  inactivate  all  sodium  channels.  
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Figure  7.    ECG  and  action  potential  waveform  under  normal  and  LQT  condition.  
A.  Action  potential  waveform  under  normal  (left)  and  LQT  disease  (Koval,  Snyder  
et  al.)  condition.    There  is  an  increase  in  action  potential  duration  and  delay  of  
ventricular  repolarization.  B.  Prolonged  QT  intervals  on  the  ECG(Koval,  Snyder  
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Figure  8.  Impaired  fast  inactivation  leads  to  the  generation  of  persistent  (late)  
sodium  current.  A  shows  the  representative  current  trace  of  normal  fast  
inactivation.  Sodium  channel  opens  and  inactivates  quickly  after  opening.  B  
indicates  the  persistent  current  generation  when  sodium  channel  fast  inactivation  
is  impaired.  Blue  color  indicating  the  non-­inactivating  persistent  current.	  	  
A BNormal'fast'inactivation Persistent'current
Peak'sodium'current Peak'sodium'current
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Figure  9  Action  potential  waveform  and  ECG  of  normal  (left)  and  Brugada  
syndrome  condition(right,  solid  line).  Under  Brugada  syndrome,  there  is  a  loss  of  
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Table  2.  Long-­QT  syndrome  (LQTS)  subtypes  and  involved  genes(Issa,  Miller  et  
al.).  
Syndrome	   Gene	   Locus	   Prevalence	  
LQTS1	   KCNQ1	   11p15.5	   42%-­‐45%	  
LQTS2	   KCNH2	   7q35	   35%-­‐45%	  
LQTS3	   SCN5A	   3p21	   8%-­‐10%	  
LQTS4	   ANK2	   4q25	   <1%	  
LQTS5	   KCNE1	   21q22.1	   <1%	  
LQTS6	   KCNE2	   21q22.1	   <1%	  
LQTS7	   KCNJ2	   17q23	   <1%	  
LQTS8	   CACNA1C	   12p13.3	   <1%	  
LQTS9	   CAV3	   3p25	   <1%	  
LQTS10	   SCN4B	   11q23	   <1%	  
LQTS11	   AKAP9	   7q21	   <1%	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Table  3  Brugada  syndrome  (BrS)  subtypes  and  involved  genes(Nielsen,  Holst  et  
al.  2013).  
Syndrome	   Gene	   Locus	   Prevalence	  
BrS1	   SCN5A	   3p21	   11%-­‐24%	  
BrS2	   GPD1-­‐L	   3p22.3	   <1%	  
BrS3	   CACNA1C	   12p13.3	   6%-­‐7%	  
BrS4	   CACNB2	   10p12.33	   4%-­‐5%	  
BrS5	   SCN1B	   19q13.11	   1%-­‐2%	  
BrS6	   KCNE3	   11q13.4	   <1%	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G.   Post-­translational  modifications  of  cardiac  sodium  channels  
VGSC  function  is  determined  by  their  intrinsic  biophysical  properties  (i.e.,  
rapid  activation  and  inactivation),  but  it  can  also  be  regulated  by  post-­
translational  modifications.  Nav1.5  is  the  target  of  many  post-­translational  
modifications,  including  glycosylation,  phosphorylation,  methylation,  acetylation,  
redox  modifications,  and  ubiquitination  (Marionneau  and  Abriel  2015).  Because  
of  the  modern  protein  analysis  technologies  like  mass  spectrometry,  we  are  able  
to  study  the  precise  location  of  post-­translational  modification  sites  and  
consensus  sequence  among  different  channel  subtypes,  leading  to  a  better  
understanding  of  the  mechanistic  details  of  these  regulations.    
Phosphorylation  is  the  most  extensively  studied  post-­translational  
modification  of  Nav1.5.  Various  protein  kinases  have  been  identified  to  modulate  
different  aspects  of  sodium  channel  function  through  diverse  pathways  including  
Ca2+/Calmodulin-­dependent  serine/theronine  protein  kinase  (CAMK)(Aiba,  
Hesketh  et  al.  2010,  Ashpole,  Herren  et  al.  2012,  Koval,  Snyder  et  al.  2012),  
protein  kinase  A  and  C  (PKA  and  PKC)(Qu,  Rogers  et  al.  1994,  Murray,  Hu  et  al.  
1997,  Shin  and  Murray  2001,  Hallaq,  Wang  et  al.  2012),  Phosphatidylinositol  3-­
Kinase  (PI3K)(Park,  Leong  et  al.  1999,  Lu,  Wu  et  al.  2012,  Lu,  Jiang  et  al.  2013),  
Adenosine  Monophosphate-­activated  Protein  Kinase  (APMK)(Light,  Wallace  et  
al.  2003).  Many  of  the  phosphorylation  sites  that  have  been  identified  were  
located  in  the  first  intracellular  linker  loop  (DI  to  DII  linker,  Figure  10)  and  a  
number  of  them  was  found  to  be  conserved  among  different  species  and  
subtypes(Marionneau,  Lichti  et  al.  2012).  
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Glycosylation,  another  common  post-­translational  modification  of  ion  
channels,  is  the  enzymatic  process  that  attaches  glycans  to  ion  channel  proteins.  
Glycosylation  of  Nav1.5  was  determined  20  years  ago  by  Cohen  and  
Levitt(Cohen  and  Levitt  1993).  N-­linked  glycans  (attached  to  a  nitrogen  of  
asparagine)  and  O-­linked  glycans  (attached  to  the  hydroxyl  oxygen  of  serine,  
threonine)  are  often  terminated  by  sialic  acids  which  can  alter  voltage-­gated  
sodium  channel  function  through  their  negative  charges.  It  has  been  shown  that  
sialylation  shifts  the  voltage-­dependence  of  activation  and  inactivation  towards  
hyperpolarized  potentials,  enhances  the  rate  of  fast  inactivation  and  reduces  the  
rate  of  recovery  from  fast  inactivation  (Bennett  2002,  Johnson,  Montpetit  et  al.  
2004).  Pathophysiologically,  reduced  cardiac  sodium  channel  sialylation  has  
been  shown  to  shorten  the  cardiomyocyte  refractory  time  and  enhance  
susceptibility  to  ventricular  arrhythmias  by  slowing  fast  inactivation  and  
increasing  the  rate  of  recovery  from  inactivation  (Ednie,  Horton  et  al.  2013).    
Ubiquitination,  another  well  studied  post-­translational  modification  of  
Nav1.5,  refers  to  the  enzymatic  process  in  which  an  ubiquitin  protein  is  attached  
to  the  sodium  channel  protein.  This  process  is  closely  associated  with  sodium  
channel  internalization.  Ubiquitination  of  Nav1.5  has  been  demonstrated  from  
both  in  vitro  and  in  vivo  studies(van  Bemmelen,  Rougier  et  al.  2004,  Rougier,  
Albesa  et  al.  2010,  Laedermann,  Decosterd  et  al.  2014).  While  many  studies  
have  suggested  that  regulation  of  ubiquitination  of  Nav1.5  could  lead  to  an  
altered  surface  expression  level  of  Nav1.5  in  cardiac  cells(Kang,  Zheng  et  al.  
2009,  Laedermann,  Cachemaille  et  al.  2013,  Rougier,  Gavillet  et  al.  2013),  the  
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detailed  mechanism  involved  in  this  process  and  the  study  of  its  clinical  
relevance,  is  still  lacking.  
Arginine  methylation  of  Nav1.5  in  stable  cell  lines  and  human  ventricles  
was  determined  recently  using  mass  spectrometry(Beltran-­Alvarez,  Pagans  et  al.  
2011,  Beltran-­Alvarez,  Tarradas  et  al.  2014).  Studies  revealed  that  arginine  
R513,  R526,  and  R680,  located  in  the  DI  and  DIl  intracellular  linker  of  cardiac  
sodium  channel,  are  subject  to  arginine  methylation.  Nav1.5  methylation  also  
enhances  cell  surface  expression  of  Nav1.5  and  sodium  current  density  (Beltran-­
Alvarez,  Espejo  et  al.  2013).    
Although  many  post-­translational  modifications  of  Nav1.5  have  been  
extensively  studied,  the  regulation  of  VGSCs  by  lipid  modifications  is  poorly  
understood.  Our  research  is  of  great  importance  that  it  provides  new  insights  into  
how  post-­translational  lipid  modification  regulates  Nav1.5  activities  and  
influences  cardiac  excitability.    
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Figure  10.  Localization  of  post-­translational  modification  sites  on  the  human  
cardiac  NaV1.5  using  in  silico  and/or  in  vitro  analyses  (A)  and  native  proteomic  
analyses  from  cardiac  tissues  (B)  16  sites  were  identified  using  in  silico/in  vitro  
analyses,  and  thirteen  were  identified  using  native  proteomics.  Five  sites  (pS484,  
pS525,  meR526,  pS571  and  pS664)  have  been  confirmed  by  MS.  This  figure  is  
from  the  review  paper  ‘Regulation  of  the  cardiac  Na+  channel  NaV1.5  by  post-­
translational  modifications’  (Marionneau  and  Abriel  2015).  
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H.   Palmitoylation  of  ion  channel  proteins  
Palmitoylation  has  been  recognized  as  an  important  post-­translational  
mechanism  for  the  regulation  of  various  membrane  proteins,  but  our  knowledge  
of  how  palmitoylation  regulates  ion  channels  is  limited(Shipston  2011).  Protein  S-­
Palmitoylation  involves  the  addition  of  a  16-­carbon  palmitic  acid  chain  to  an  
intracellular  cysteine  residue  through  a  thioester  linkage(Figure  11).    
S-­Palmitoylation  is  a  reversible  process  that  can  dynamically  regulate  
protein  life  cycle  and  function(Shipston  2011).  Multiple  enzymes  that  facilitate  the  
palmitoylation  process  have  been  identified  in  recent  years  (Lobo,  Greentree  et  
al.  2002,  Roth,  Feng  et  al.  2002).  Palmitoyltransferases  (PATs),  the  catalytic  
enzymes  for  protein  palmitoylation,  form  a  diverse  family  of  proteins  (23  
members  in  mammals)(Fukata,  Fukata  et  al.  2004,  Greaves  and  Chamberlain  
2011,  Korycka,  Lach  et  al.  2012).  PATs  are  characterized  by  the  presence  of  a  
aspartate-­histidine-­histidine-­cysteine  (DHHC)  motif  within  a  cysteine-­rich  domain  
(Salaun,  Greaves  et  al.  2010).  The  reverse  process,  depalmitoylation,  is  
mediated  by  acyl  protein  thioesterases  (APTs)(Zeidman,  Jackson  et  al.  2009).  
According  to  previous  studies,  non-­enzymatic  palmitoylation  could  be  possible  
but  is  very  rare  and  only  reported  in  vitro(O'Brien,  St  Jules  et  al.  1987,  Ross  and  
Braun  1988,  Mollner,  Ferreira  et  al.  1998).  
Palmitoylation  is  involved  in  various  phases  of  ion  channel  life  cycle,  
including  synthesis,  maturation,  trafficking,  membrane  localization,  internalization  
and  recycling.  Palmitoylation  plays  an  important  role  in  the  biosynthesis  of  brain  
voltage-­gated  sodium  channels  (Nav1.2)  and  potassium  channels	  to  regulate  
channel  maturation  and  quality  control  (Schmidt  and  Catterall  1987,  Zhang,  
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Foster  et  al.  2007).  The  formation  of  ligand-­binding  sites  in  nicotinic  acetylcholine  
receptors  is  also  regulated  by  palmitoylation  (Drisdel,  Manzana  et  al.  2004,  
Alexander,  Govind  et  al.  2010).  Palmitoylation  regulates  trafficking  of  glutamate  
channels(Hayashi,  Rumbaugh  et  al.  2005,  Hayashi,  Thomas  et  al.  2009)  and  the  
spatial  organization  of  aquaporin  channels(Suzuki,  Nishikawa  et  al.  2008).  The  
addition  of  palmitic  acid  also  regulates  protein  hydrophobicity  and  facilitates  
association  to  the  membrane.  However,  few  studies  have  focused  on  how  
palmitoylation  directly  alters  channel  biophysical  activity  at  the  membrane.  
Palmitoylation  of  the  intracellular  linker  between  domain  II  and  III  in  Kv1.1  has  
been  shown  to  increase  the  intrinsic  voltage  sensitivity  of  the  channel(Gubitosi-­
Klug,  Mancuso  et  al.  2005).  In  1987,  brain  sodium  channel  palmitoylation  was  
identified  to  occur  in  the  early  stages  of  biosynthesis(Schmidt  and  Catterall  
1987).  Electrophysiological  data  indicates  that  two  putative  palmitoylation  sites  in  
a  Nav1.2  channel  likely  regulate  brain  sodium  channel  activity  as  well  as  
modulating  channel  affinity  to  PaurTx3  and  ProTx-­II  toxin  (Bosmans,  Milescu  et  
al.  2011).    
The  functional  effect  of  ion  channel  palmitoylation  is  dependent  on  both  
the  channel  type  and  the  location  of  the  palmitoylation  sites.  Palmitate  lipid  may  
attach  to  different  locations  including  C-­terminus,  N-­terminus,  juxta-­
transmembrane  region  or  intracellular  loop,  leading  to  the  distinct  alteration  in  
various  aspects  of  ion  channel  protein  function  (Shipston  2014).  It  is  still  unclear  
how  palmitoylation  alter  the  functional  activity  of  ion  channel  protein.  One  
hypothesized  mechanism  is  that  the  palmitate  molecules  interact  with  the  
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membrane  lipids  (Figure  12),  changing  the  lipid  membrane  environment  
surrounding  the  targeted  channel  as  well  as  impacting  protein  configuration,  thus  
potentially  modulating  channel  activity.    
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Figure  11.  A  schematic  illustration  of  the  dynamic  regulation  of  protein  
palmitoylation.  Palmitoylation  is  a  reversible  process  due  to  the  labile  thioester  
bond.  Palmitoyltransferase  mediates  the  palmitoylation  process  with  the  
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Figure  12.  Schematic  representation  of  palmitoylation  on  different  locations  of    
ion  channel  proteins.  Cysteine  palmitoylation  can  occur  on  C-­terminal  (A),  N-­
terminal  (B),  juxta-­transmembrane  region  (C)  or  intracellular  loop  of  ion  channel  
proteins.  This  figure  is  adapted  and  slightly  modified  from  ‘Ion  channel  regulation  
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I.   Hypothesis  and  specific  aims   
      Previous  research  has  demonstrated  that  palmitoylation  plays  an  essential  
role  in  regulating  ion  channel  function.  However,  very  few  studies  demonstrate  
how  palmitoylation  directly  alters  ion  channel  biophysical  activity  at  the  
membrane  and  its  physiological  and  pathological  consequences.  One  previous  
study  shows  two  putative  palmitoylation  sites  in  a  Nav1.2  channel  modulates  
brain  sodium  channel  activity  by  regulating  channel  inactivation  and  channel  
pharmacology  (Bosmans,  Milescu  et  al.  2011).  However,  the  direct  biochemical  
evidence  of  sodium  channel  palmitoylation  is  lacking  in  this  study  and  the  
physiological  consequence  of  the  sodium  channel  palmitoylation  is  still  unknown.  
It  raises  several  questions  for  us:  1.  is  it  possible  to  have  direct  biochemical  
determination  of  sodium  channel  palmitoylation;;  2.  whether  palmitoylation  of  
other  sodium  channel  subtypes  would  also  occur  and  would  that  occur  in  
conserved  sites;;  3.  what  is  the  physiological  consequence  of  voltage-­gated  
sodium  channel  palmitoylation  and  could  palmitoylation  be  associated  with  any  
disease  phenotype  under  specific  pathological  conditions.    
      Overall,  the  central  hypothesis  of  this  dissertation  project  is  that  
palmitoylation  can  regulate  cardiac  sodium  channel  activity  and  cardiac  
excitability,  and  can  be  a  novel  pathomechanism  underlying  cardiac  arrhythmias.  
The  hypothesis  consists  of  three  specific  aims.    
      The  first  specific  aim  is  to  show  the  direct  biochemical  evidence  of  cardiac  
sodium  channel  palmitoylation.  Few  studies  have  demonstrated  ion  channel  
palmitoylation  with  biochemical  results.  Brain  sodium  channel  palmitoylation  has  
been  shown  with  metabolic  labelling  of  palmitate  (Schmidt  and  Catterall  1987).  
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However,  these  experiments  usually  require  exposure  time  from  one  month  to  
half  a  year.  In  recent  years,  development  of  the  acyl-­biotin  exchange  assay  
(ABE)  enables  much  faster  detection  of  protein  palmitoylation.  Hence,  this  
method  was  applied  in  most  of  our  biochemistry  experiments.  We  also  performed  
experiments  using  the  click  chemistry  method  and  detailed  comparison  of  three  
methods  were  discussed  in  Section  IV  B.  Bioinformatics  tools  and  ABE  assay  
were  used  to  determine  the  potential  palmitoylation  sites.    
      My  second  specific  aim  focuses  on  the  alteration  of  cardiac  sodium  
channel  functions  by  palmitoylation.  Sodium  channel  biophysical  properties,  
including  fast  inactivation,  voltage-­dependent  activation  and  inactivation,  
recovery  from  inactivation,  slow  inactivation  and  recovery  from  slow  inactivation  
were  assessed  to  investigate  palmitoylation  effect  on  sodium  channel  function.    
      Although  palmitoylation  is  likely  an  important  regulator  of  ion  channel  
activity,  evidence  for  the  direct  influence  of  palmitoylation  on  cellular  excitability,  
and  its  potential  involvement  in  cardiac  sodium  channelopathies,  is  lacking.  
Therefore,  in  our  final  specific  aim,  we  investigated  palmitoylation  effect  on  
cardiac  myocyte  excitability.  Cardiac  sodium  channel  biophysical  properties  and  
action  potential  parameters  were  studied  under  non-­treatment,  depalmitoylated  
and  enhanced  palmitoylation  condition.      
      Overall,  the  objective  of  this  project  is  to  understand  palmitoylation  of  
cardiac  sodium  channel  protein  and  its  physiological  relevance.  This  dissertation  
addresses  the  following  questions  of  this  project:  1)  whether  Nav1.5  is  
palmitoylated  in  heterologous  expression  system  and  cardiac  tissues;;  2)  how  
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does  palmitoylation  alter  Nav1.5  functions;;  3)  where  are  the  palmitoylation  sites  
on  Nav1.5;;  4),  how  does  palmitoylation  regulate  cardiac  excitability  and  its  
relevance  with  cardiac  arrhythmia  disease.  This  study  adds  important  insights  to  
the  study  of  cardiac  sodium  channel  post-­translational  modifications  and  provides  
previously  unrevealed  cellular  and  ionic  mechanisms  underlying  
arrhythmogenesis.
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II.   MATERIALS  AND  METHODS  
A.   Ethical  information  and  animal  protocols    
Human  embryonic  kidney  (HEK293)  cells  were  obtained  from  ATCC  
(Manassas,  USA).  Use  of  HEK293  cells  was  approved  by  the  Institutional  
Biosafety  Committee  and  conformed  to  the  ethical  guidelines  for  the  National  
Institutes  of  Health  for  the  use  of  human  derived  cell  lines.    
The  use  of  animals  was  in  compliance  with  the  Guide  for  the  Care  and  
Use  of  Laboratory  Animals  published  by  the  US  National  Institutes  of  Health  and  
was  approved  by  the  Indiana  University  School  of  Medicine  Animal  Care  and  Use  
Committee.  
B.   Animals.    
      Postnatal  Day  1  Sprague  Dawley  rats  were  obtained  from  Harlan-­Sprague  
Dawley,  Inc.  (Indianapolis,  IN,  USA).  Animals  were  kept  in  the  Laboratory  of  
Animal  Source  Center  and  used  on  the  day  of  arrival.    
C.   Chemicals  
      2-­Br-­palmitate,  Palmitic  acid,  Lidocaine  and  Mexiletine  hydrochloride  were  
obtained  from  Sigma-­Aldrich.  Flecainide  and  Ranolazine  were  purchased  from  
Abcam.    
D.   Experimental  cDNA  constructs    
      hNav1.5  constructs  were  introduced  into  pcDNA3.1(+)  with  the  CMV  
promoter  using  HindIII  and  XbaI  restriction  enzyme  sites.    
E.   Mutagenesis  of  voltage-­gated  sodium  channels  
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      Specific  mutation  sites  were  introduced  using  the  QuikChange  II  XL  site-­
directed  mutagenesis  kit  according  to  the  manufacturer's  instruction.Mutagenesis  
primers  were  designed  to  introduce  the  specific  base  pair  change  into  wild  type  
hNav1.5  channel  cDNA.  All  the  constructs  were  sequenced  (ACGT  Inc.  
Wheeling,  IL,  USA)  to  confirm  the  specific  mutation  at  target  sites.  Primers  that  
were  used  to  generate  human  Nav1.5  cDNA  mutation  constructs  are  included  in  
Table  4.  
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C981F  forward   CCACCTGGGATTTCTTCTGTGGTCTCCTGC  
C981F  reverse   GCAGGAGACCACAGAAGAAATCCCAGGTGG  
C981A  forward   CCACCTGGGATTTCGCCTGTGGTCTCCTGC  
C981A  reverse   GCAGGAGACCACAGGCGAAATCCCAGGTGG  
C1178A  forward   GCGCTGTCCCGCCTGTGCGGTGGACACCACA  
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F.              HEK293  cell  culture    
      HEK293  and  HEK293T  cells  (ATCC  CRL-­1573  and  CRL-­3216,  
respectively,  Manassas,  VA,  USA)  were  cultured  in  Dulbecco's  Modified  Eagle  
Medium  (Life  Technologies,  Grand  ISLAND,  NY,  USA)  supplemented  with  10%  
fetal  bovine  serum  (Atlanta  Biologicals,  Laurenceville,  GA,  USA)  and  1%  
penicillin/streptomycin  (Invitrogen,  Grand  Island,  NY,  USA).  Cells  were  kept  at  
37°C  incubator  with  5%  CO2.  
G.   Harvest,  isolation  and  culture  of  neonatal  rat  cardiomyocytes    
      Sprague  Dawley  rat  pups  of  postnatal  day  1  were  used  in  the  harvest,  
isolation  and  culture  of  rat  cardiomyocytes.  After  pups  were  sacrificed,  hearts  
were  collected  and  placed  in  calcium  and  magnesium-­free  ice-­cold  PBS.  Hearts  
were  gently  squeezed  using  flat  tip  forceps  to  remove  the  remaining  blood.  The  
ventricles  were  cut  and  transferred  into  1.5ml  eppendorf  tubes  and  pre-­warmed  
PBS  containing  0.5mg/ml  collagenase  (Worthington,  Lakewood,  NJ,  USA)  was  
added  as  the  digestion  solution.  The  ventricle  tissues  were  cut  into  small  pieces  
and  transferred  into  a  new  15ml  conical  tube  containing  the  same  digestion  
solution.  The  cardiac  tissues  were  further  digested  in  the  37°C  water  bath  for  45  
minutes  with  a  gentle  mix  every  5  minutes.  The  cell  suspension  was  collected  
every  15  minutes  and  fresh  digestion  solution  was  added  each  time.  After  
collecting  cell  suspension,  1  ml  of  horse  serum  was  added  to  terminate  the  
digestion.  Cell  suspension  was  centrifuged  at  900  rpm  for  10  minutes.  The  
supernatant  was  discarded  and  the  palette  was  resuspended  with  10ml  cell  
culture  media  (DMEM+10%FBS).  The  tube  was  centrifuged  second  time  at  the  
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same  speed  for  10  minutes.  The  supernatant  was  discarded  again  and  the  cells  
were  mixed  into  suspension  with  10ml  cell  culture  media.  Collected  cells  were  
plated  in  10cm  cell  culture  dishes  for  2hrs  to  allow  fibroblast  cells  attach  and  then  
transferred  to  24  wells  plates  with  0.2%  gelatin  pre-­coated  coverslips.  Cells  were  
incubated  under  normal  cell  culture  conditions  (37°C,  5%  CO2)  in  Dulbecco's  
Modified  Eagle  Medium  supplemented  with  10%  fetal  bovine  serum.  After  24  
hours  incubation,  the  culture  medium  was  replaced  with  a  low  serum  medium  
(0.5%  horse  serum,  0.5%  fetal  bovine  serum)  to  prevent  hypertrophy(Simpson,  
McGrath  et  al.  1982).  Cardiomyocytes  were  cultured  for  up  to  72  hours.  
H.   Solutions  
1.     Standard  extracellular  bathing  solution  for  HEK293  cell  voltage  
clamp  recordings  
      The  standard  external  bathing  solution  for  sodium  current  recording  
contained  (in  mM)  140  NaCl,  1  MgCl2,  1  CaCl2,  3  KCl,  and  10  HEPES,  pH  7.3  
adjusted  with  1N  NaOH.  The  osmolarity  was  adjusted  to  276  Osm.    
2.     Standard  intracellular  electrode  solution  for  HEK293  cell  voltage  
clamp  recordings    
      The  standard  pipette  solution  contained  (in  mM)  140  CsF,  10  NaCl,  1.1  
EGTA,  and  10  HEPES,  pH  7.3  (adjusted  with  CsOH)  and  the  osmolarity  was  
adjusted  to  293  Osm.  
3.     Standard  extracellular  bathing  solution  for  cardiomyocytes  voltage  
clamp  recordings    
      The  external  bathing  solution  of  cardiomyocyte  whole  cell  voltage  clamp  
   47  
recordings  contains  (mM):  120  NaCl,  1.2  MgCl2,  1.5  CaCl2,  10  Hepes,  10  
tetraethylammonium-­chloride,  5.0  sucrose,  5.0  glucose  and  0.05  CdCl2,  pH  was  
adjusted  to  7.4  with  NaOH.  Osmolarity  of  the  solution  was  adjusted  to  283  Osm.  
Tetraethylammonium-­chloride  and  CdCl2  were  used  to  block  potassium  and  
calcium  currents  in  myocytes  in  order  to  focus  on  recording  whole  cell  sodium  
currents.  
4.     Standard  intracellular  electrode  solution  for  cardiomyocytes  voltage  
clamp  recordings  
      The  pipette  solution  contained:  120  CsF,  5.0  NaCl,  2.0  MgCl2,  10  Hepes  
and  10  EGTA.  pH  was  adjusted  to  7.3  with  CsOH.  The  osmolarity  of  the  solution  
was  adjusted  to  276  Osm).  
5.     Standard  extracellular  bathing  solution  for  cardiomyocytes  action  
potential  recordings    
      The  bath  solution  for  the  whole  cell  current  clamp  recordings  on  
cardiomyocytes  contained  (mM):  NaCl  126,  KCl  5.4,  Hepes  10,  NaH2PO4  0.33,  
MgCl2  1.0,  CaCl2  1.8  and  glucose  10.  pH  was  adjusted  with  NaOH  to  7.3.  The  
osmolarity  of  the  solution  was  adjusted  to  300  Osm.  
6.     Standard  intracellular  electrode  solution  for  cardiomyocytes  action  
potential  recordings  
      The  pipette  solution  used  in  current-­clamp  studies  contained  (mM):  KCl  
20,  potassium  aspartate  110,  MgCl2  1.0,  Hepes  5.0,  EGTA  10  and  Na2-­ATP  5.0.  
pH  was  adjusted  to  7.2  with  KOH.  The  osmolarity  of  the  solution  was  adjusted  to  
295  Osm.  
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I.   Whole  cell  voltage-­clamp  recordings  from  HEK293  cells.  
      The  coverslip  was  placed  in  the  middle  of  the  patch-­clamp  recording  
chamber  containing  300ul  extracellular  bath  solution.  All  recordings  were  
performed  at  room  temperature.  Data  were  acquired  using  HEKA  EPC-­10  patch-­
clamp  amplifier  and  Pulse  program  v8.65  (HEKA  Electronic,  Lambrecht/Pfalz,  
Germany).  Glass  pipettes  were  pulled  and  polished  with  resistance  between  0.9  
and  2  MΩ.  After  the  pipettes  attach  cell  surface,  Gigaohm  was  formed  by  
applying  slight  negative  pressure  through  the  glass  pipettes.  Once  a  gigaohm  or  
greater  seal  was  formed  between  the  cell  of  interest  and  the  recording  pipette,  
the  whole  cell  configuration  was  obtained  using  gentle  suction  pulses.  
Recordings  were  started  around  5  minutes  after  forming  whole  cell  configuration  
to  allow  sufficient  equilibration  of  the  intracellular  solution  and  the  pipette  
solution.  In  the  conductance-­voltage  relationship  studies,  the  cells  were  held  at  -­
100  mV  then  a  100ms  pulse  from  -­100mV  to  +45  mV  with  5mV  increments  was  
used  to  elicit  the  currents.  In  steady-­state  inactivation  studies,  cells  were  held  at  -­
100  mV  and  then  stepped  to  an  inactivating  prepulse  from  -­150  mV  to  -­10  mV  
with  10  mV  increments  for  500  ms.  The  channels  that  remain  available  after  each  
inactivating  prepulse  were  evaluated  by  the  peak  current  produced  during  a  test  
pulse  to  0  mV  for  20  ms.  In  the  recovery  from  inactivation  protocol,  500ms  
depolarization  pulse  to  +20mV  was  induced  to  fully  inactivate  the  channel,  and  
recovery  was  assessed  by  a  test  pulse  from  -­100mV  to  0mV  with  a  varying  time  
between  pulses  (0-­50ms).  
J.   Whole  cell  voltage-­clamp  recordings  from  neonatal  cardiomyocytes.    
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      Whole-­cell  cardiac  sodium  currents  were  recorded  at  room  temperature  
from  neonatal  cardiomyocytes  within  24-­72  h  after  cell  culture.  Voltage-­clamp  
protocols  used  were  similar  as  previously  described  in  voltage-­clamp  recordings  
in  HEK293  cells.    
K.   Whole  cell  current-­clamp  recordings  from  neonatal  cardiomyocytes.  
      Action  potentials  were  elicited  by  2  ms  stimulus  pulses  at  a  frequency  of  1  
Hz.  Spontaneous  action  potential  generation  was  recorded  given  the  current  
input  at  0  pA.  Action  potential  recordings  were  started  5  min  after  establishing  the  
whole  cell  configuration.  No  TTX  was  added  to  the  external  recording  solution  for  
action  potential  studies.    
L.              Transient  transfection  and  preparation  of  stably  transfected  HEK293  
cells    
      Cells  were  transfected  using  the  calcium  phosphate  precipitation  method.  
The  transfection  reagents  containing  2X  HEPES  buffer  (280  mM  NaCl,  1.5mM  
Na2HPO4,  50mM  Na-­HEPES,  pH=7),  double  distilled  water;;  2  M  CaCl2  was  
mixed  with  DNA  and  eGFP.  Each  tube  contains  40  µl  HEPES,  4.5  µl  DNA  (1  
µg/µl),  0.5  µl  eGFP  (1  µg/µl),  5  µl  CaCl2  and  30  µl  double  distilled  water.  The  
mixture  of  DNA  and  calcium  phosphate  was  kept  in  the  cell  culture  hood  for  30  
minutes  before  added  to  the  medium.  After  30  minutes,  the  80  µl  DNA  and  
calcium  phosphate  mixture  was  added  to  2  ml  Dulbecco's  Modified  Eagle  
Medium.  Then  the  cell  culture  medium  was  replaced  by  the  Dulbecco's  Modified  
Eagle  Medium  containing  DNA  and  calcium  phosphate  mixture.  After  three  hours  
incubation,  the  culture  medium  was  replaced  again  with  standard  culture  
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medium.  Patch-­clamp  recordings  were  performed  24–48  h  after  transfection.  
Cells  were  selected  based  on  the  expression  of  green  fluorescence  protein.  
Stable  cell  lines  were  generated  using  similar  procedure  without  adding  eGFP  to  
the  DNA  and  calcium  phosphate  mixture.  At  48-­72  hours  post  transfection,  cells  
were  moved  to  100  mm  dishes  and  G418  was  added  to  the  dish  at  400  µg/ml  
concentration.  Typically,  culture  medium  with  selection  antibiotic  was  replaced  
every  4  days  for  up  to  four  weeks.  The  cell  colonies  were  transferred  and  
cultured  for  further  functional  assessments.    
M.   Preparation  of  cell  lysate  and  tissue  lysate.  
      The  use  of  animals  was  in  compliance  with  the  Guide  for  the  Care  and  
Use  of  Laboratory  Animals  published  by  the  US  National  Institutes  of  Health  and  
was  approved  by  the  Indiana  University  School  of  Medicine  Animal  Care  and  Use  
Committee.  Heart  tissue  (300mg)  from  Sprague  Dawley  rats  was  homogenized  in  
10  ml  lysis  buffer  (20mM  Hepes,  20mM  NaCl,  5mM  EDTA,  1%  Triton  X-­100,  500  
µl  protease  inhibitor  cocktail  set  V).  Tissues  were  cut  into  small  pieces  and  lysed  
using  electric  homogenizer  (Wheaton).  The  homogenate  was  centrifuged  at  4°C  
at  13,200  X  g,  and  the  supernatant  was  collected.  Aliquots  of  supernatant  were  
stored  at  −80°C.  
      Cell  lysate  was  prepared  using  the  same  lysis  buffer.  Cells  were  washed  
three  times  with  ice-­cold  PBS  (Thermo  Fisher  Scientific).  1.5  ml  lysis  buffer  was  
added  to  each  10mm  dish  after  the  third  wash  and  incubated  for  5  mins  on  ice.  
Cell  lysates  were  collected  using  1.5ml  eppendorf  tubes  and  sonicated  to  agitate  
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and  disrupt  the  cell  membranes.  The  lysates  were  centrifuged  at  4°C  at  2,000  g,  
and  the  supernatant  was  collected  and  store  at  -­80°C.    
N.   Acyl  biotin  exchange  method    
      Cell  lysate  was  treated  overnight  using  N-­ethylmaleimide  (NEM)  to  block  
free  cysteines  while  rotating  at  4°C  to  ensure  complete  cysteine  alkylation.  Next  
day,  the  insoluble  component  was  discarded  after  centrifuge  at  13500  X  g  for  5  
mins.  The  cell  lysate  was  washed  by  chloroform-­methanol  precipitation  to  
remove  excess  chemicals.  The  protein  interface  was  washed  twice  using  
methanol.  After  the  last  centrifugation,  protein  was  dissolved  in  500ul  PBS  
containing  1%  SDS.  The  soluble  protein  was  divided  into  two  equal  groups,  each  
containing  250µl  and  treated  with  either  NH2OH  (0.7M  Hydroxylamine,  1mM  
biotin,  0.2%  Triton  X-­100,  500µl  protease  inhibitor  cocktail  set  V)  or  control  
solution  (200mM  Tris,  1mM  biotin,  0.2%  Triton  X-­100,  500µl  protease  inhibitor  
cocktail  set  V)  solution.  The  reaction  was  carried  out  in  a  dark  environment  for  
1hr.  The  remaining  chemicals  were  removed  using  a  chloroform  methanol  wash  
and  resolubilized  in  PBS  containing  1%  Triton  X-­100  and  0.2%  SDS.  The  
biotinylated  proteins  were  captured  by  streptavidin-­Sepharose  (GE  Healthcare)  
beads  at  4°C  overnight.  Beads  were  washed  four  times  with  PBS  containing  1%  
Triton  X-­100  and  0.2%  SDS  the  next  day.  Electrophoresis  loading  buffer  (LDS  
containing  2%  β-­mercaptoethanol)  was  added  to  each  sample  and  heated  for  10  
min  at  80°C.  
O.   Metabolic  labeling  and  detection  of  Nav1.5  palmitoylation  
      HEK293  cells  with  stable  expression  of  human  Nav1.5  channels  were  
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cultured  in  100mm  dishes,  while  untransfected  HEK293  cells  were  used  as  
negative  controls.  Each  dish  was  labeled  with  120μCi/ml  [3H]  palmitic  acid  
(PerkinElmer)  in  DMEM  containing  10%  FBS  overnight.  The  medium  was  
removed  the  following  day  and  cells  were  rinsed  3  times  with  PBS.  Cell  lysates  
were  collected  and  added  to  the  protein  G  agarose  bead,  which  was  prepared  by  
coupling  Nav1.5  pan  antibody  overnight.  After  four  hours’  incubation,  the  lysate  
was  removed,  the  protein-­G  beads  were  washed  3  times  with  lysis  butter  (20mM  
Hepes,  20mM  NaCl,  5mM  EDTA,  1%  Triton  X-­100,  1×protease  inhibitor  cocktail  
set  V(Millipore)),  and  proteins  were  eluted  from  the  beads  using  4X  LDS  sample  
buffer  with  2%  beta-­mercaptoethanol.  Samples  were  then  analyzed  according  to  
the  standard  denaturing  PAGE  protocol  (Novex  Gel  System,  Life  Technologies,  
Carlsbad,  CA,  USA).  The  gel  was  washed  three  times  with  hot  water  and  stained  
with  Coomassie  Blue  for  1  hour.  In  order  to  increase  the  sensitivity  of  tritium  
detection,  protocols  using  EN3HANCE  (PerkinElme,  Waltham,  MA,  USA)  were  
followed  based  on  manufacturer’s  instructions.  To  precipitate  the  fluor  in  the  gel,  
gel  was  washed  with  10%  PEG  800  and  1%  glycerol  with  agitation  for  30  
minutes.  To  further  prevent  the  gel  from  cracking,  the  gel  was  incubated  in  gel  
dying  buffer  (30%  Ethanol,  10%  glycerol)  for  30  minutes  and  transferred  onto  
Whatman  filter  paper  for  vacuum  drying  (ThermoSavant,  Waltham,  MA,  USA).  
Dried  gels  were  exposed  to  Biomax  high  sensitivity  film  (Sigma-­Aldrich,  St.  Louis,  
MO)  and  were  stored  at  -­80°C  freezer  for  approximately  3  weeks  before  
developing  the  film.  
P.   Gel  Electrophoresis  and  Western  Immunoblotting  
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      Samples  were  solubilized  in  4×LDS  sample  buffer  and  β-­mercaptoethanol.  
Gel  electrophoresis  and  protein  transfer  was  performed  according  to  the  
standard  protocol  (Life  Technologies,  Carlsbad,  CA,  USA).  4-­12%  gradient  
precast  gels  (Life  Technologies,  Carlsbad,  CA,  USA)  were  used  for  protein  
seperation  and  a  constant  voltage  of  200mV  was  applied.  Sodium  channel  pan  
antibody  (1:1000  diluted,  Sigma-­Aldrich,  St.  Louis,  MO)  was  used  as  a  primary  
antibody  to  detect  Nav1.5  signal.  In  the  cardiac  tissue  study,  caveolin3  antibody  
(1:5000  diluted,  BD  Biosciences,	  San  Jose,  CA,  USA)  was  used  to  detect  
caveolin  expression  in  the  cardiac  tissues.  The  fluorescently-­labeled  secondary  
antibody  (IRDye  800CW  goat  anti-­mouse,  1:5000  diluted)  was  obtained  from  Li-­
Cor  (Lincoln,  Nebraska,  USA).  
Q.   Coomassie  staining  and  silver  staining  of  protein  gels  
      Coomassie  staining  was  performed  right  after  gel  electrophoresis.  The  gel  
was  transferred  to  a  glass  container  filled  with  boiling  water  and  washed  for  15  
minutes.  This  step  was  repeated  three  times  before  staining  solution  (Coomassie  
G-­250  Staining)  was  added  into  the  gel.  After  1.5  hours,  the  staining  solution  was  
removed  by  washing  with  distilled  water  for  2  hours.    
      Silver  staining  was  performed  using  the  mass  Spectrometry  compatible  
silver  staining  kit  (Thermo  Fisher  Scientific,  Waltham,  MA,  USA).  The  gel  was  
washed  twice  with  5  minutes  each  time  after  the  gel  electrophoresis.  Fixing  
solution  (30%  ethanol,  10%  acetic  acid)  was  then  added  to  the  gel  and  incubated  
for  30  minutes  (replace  with  refresh  fixing  solution  after  15  minutes).  The  
remaining  solution  was  removed  by  washing  with  ethanol  wash  (twice,  5  minutes  
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each  time)  and  ultrapure  water  (twice,  5  minutes  each  time).  The  gel  was  then  
incubated  in  sensitizer  working  solution  (50μL  sensitizer  and  25  mL  water)  for  
exactly  1  minute,  followed  by  washing  in  ultrapure  water  (twice,  1  minute  each  
time).  Next,  the  gel  was  incubated  with  enhancer  (0.25  mL  enhancer  and  25  mL  
stain)  for  5  minutes  and  washed  with  ultrapure  water  twice  (20  seconds  each).	  
Developer  working  solution  (0.25mL  enhancer  and  25mL  developer)  was  added  
to  the  gel  and  incubated  until  the  protein  bands  appear  (about  2  minutes).  As  
soon  as  the  protein  band  appears  and  reaches  desire  intensity,  the  developer  
working  solution  was  replaced  by  the  stop  solution  (5%  acetic  acid),  followed  by  
a  brief  wash  and  incubation  in  acetic  acid  for  10  minutes.  After  a  final  wash  with  
ultrapure  water  for  10  minutes,  the  protein  band  was  excised  immediately  using  a  
clean  scalpel  and  placed  in  0.5  mL  microcentrifuge  tubes.  
R.   Copper  (I)-­catalyzed  azide-­alkyne  cycloaddition  reaction  (click  
chemistry).      
      Untransfected  HEK293  cell  and  HEK293  cells  stably  expressing  Nav1.5  
channels  were  cultured  in  DMEM  with  10%  FBS.  Cells  were  then  incubated  in  
17-­ODYA  labeling  media  (DMEM  with  10%  dialyzed  FBS  (Gemini  Bio  Products,  
West  Sacramento,  CA)  and  25mM  17-­octadecynoic  acid  (Cayman  Chemical,  
Ann  Arbor,  Michigan,  USA)  for  4  hours,  washed  with  D-­PBS  (Thermo  Fisher  
Scientific,  Waltham,  MA,  USA),  and  lysed  with  cell  lysis  buffer  (20mM  Hepes,  
20mM  NaCl,  5mM  EDTA,  1%  Triton  X-­100,  1×protease  inhibitor  cocktail  set  V  
(Millipore)).  Cleared  lysates  were  immunoprecipitated  with  anti-­Nav1.5  pan  
antibody  and  protein  G-­Sepharose  for  4  h.  The  beads  were  washed  3  times  in  
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lysis  buffer  and  resuspended  with  44μl  D-­PBS.  Click  chemistry  reagents  
containing1mM  CuSO4,  1mM  tris(2-­carboxyethyl)phosphine,  100  μM  tris[(1-­
benzyl-­1H-­1,2,3-­triazol-­4-­yl)methyl]amine  (Sigma-­Aldrich,  St.  Louis,  MO)  and  1μl  
IRDye®  680RD  Azide  (Thermo  Fisher  Scientific,  Waltham,  MA,  USA)  were  then  
added  to  the  beads.  After  one-­hour  incubation  at  room  temperature,  the  beads  
were  washed  3  times  with  D-­PBS  and  treated  with  1X  SDS  gel  loading  buffer.  
The  supernatants  were  separated  into  two  equal  amounts  of  25  μl  samples.  For  
control  experiments,  1.25  μl  of  50%  stock  of  hydroxylamine  (pH7.0)  was  added  
into  one  of  the  two  equal  amount  samples  in  order  to  remove  the  thioester-­
dependent  labeling.  The  sample  mix  was  then  incubated  at  room  temperature  for  
1  hour,  heated  at  85°C  for  10  minutes  and  analyzed  by  standard  SDS-­PAGE  gel  
electrophoresis.  In-­gel  fluorescence  of  probe-­labeled  proteins  was  detected  by  
Li-­Cor  Odyssey  CLx  Imager.  
S.   Computational  simulations  of  cardiac  myocyte  
      Computer  models  of  cardiac  AP  firing  were  employed  to  simulate  the  
impact  of  the  consequences  of  the  changes  in  channel  gating  induced  by  sodium  
channel  palmitoylation.    The  cardiac  myocyte  model  was  adapted  from  that  
previously  implemented  by  Ingemar  Jacobson  in  the  NEURON  simulation  
environment  (which  is  available  at  
http://senselab.med.yale.edu/ModelDB/ShowModel.asp?model=3800).    The  only  
changes  made  to  the  mathematical  formulations  used  in  the  model  were  to  the  
voltage-­dependent  sodium  current  (Naf  in  the  original  model).    We  ran  
simulations  with  1)  wild-­type  Nav1.5  currents,  2)  Nav1.5  currents  with  simulated  
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2-­Br-­palmitate  treatment  and  3)  Nav1.5  currents  with  simulated  palmitic  acid  
treatment.    A  Markov  model  of  Nav1.5,  based  on  the  Hodgkin-­Huxley  formulation  
of  Nav1.5  in  the  original  cardiac  model  of  AP  firing,  was  used  as  it  is  more  
amenable  to  implementation  of  the  palmitic  acid  and  2-­Br-­palmitate  effects.  This  
formulation  also  included  slow  inactivation  states.  Supplementary  Fig.  6  shows  a  
diagram  for  the  Markov  model  of  the  simulated  Nav1.5  conductance  and  Table  5  
shows  the  transition  rate  expressions  for  Nav1.5  and  the  currents  simulating  the  
two  treatment  groups.  
T.              Data  analysis  
      Whole  cell  patch  clamp  data  were  analyzed  using  the  Pulsefit  (v  8.65,  
HEKA  Electronic,  Germany),  GraphPad  Prism  (GraphPad  Software  Inc.	  La  Jolla,  
CA,  USA)  and  origin  pro  8  (Originlab  Corp,  Northampton,  MA,  USA).  All  data  
points  are  shown  as  mean±s.e.m.,  and  n  is  presented  as  the  number  of  the  
separate  experimental  cells.  Steady-­state  activation  and  inactivation  curves  were  
fitted  using  Boltzmann  equation:  I(V)=Offset+{amplitude/[1+exp((V-­V1/2)/Z)]},  in  
which  V1/2  represents  midpoint  of  activation  and  inactivation  curve.  V  stands  for  
the  test  potential  and  Z  represents  the  slope  factor.  Two  tailed,  Student's  t-­tests  
were  used  to  study  the  statistical  difference  of  the  channel  functional  parameters  
with  and  without  channel  depalmitoylation,  including  current  density,  half  maximal  
activation/inactivation,  slope  factor,  recovery  rate.  We  concluded  that  a  
significant  difference  exists  when  P  values  were  less  than  0.05.
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III．   Results  
A.   Characterization  of  cardiac  sodium  channel  palmitoylation    
1.   Characterization  of  Nav1.5  palmitoylation  in  HEK293  cells  using  acyl  
biotin  exchange  method  
To  study  whether  cardiac  sodium  channels  are  palmitoylated  in  HEK293  
cells,  we  first  use  a  non-­radioactive  acyl  biotin  exchange  (ABE)  assay  to  detect  
Nav1.5  palmitoylation.  The  basic  principles  of  ABE  assay  is  to  substitute  
palmitoylated  cysteines  with  biotin  and  to  enable  a  rapid  detection  of  dynamic  
protein  palmitoylation  by  the  measurement  of  thiol-­biotinylated  proteins(Brigidi  
and  Bamji  2013).  HEK293  cells  stably  expressing  Nav1.5  recombinant  channels  
were  used  in  the  experiment.  HEK293  cells,  which  eliminates  the  contamination  
of  endogenous  sodium  currents,  serves  as  a  simple  but  robust  expression  
system  for  Nav1.5  studies.    
Before  the  ABE  assay,  original  cell  lysates  were  collected  from  two  10mm  
dishes  of  Nav1.5  stable  cells.  An  additional  two  dishes  of  untransfected  HEK293  
cells  were  used  as  a  control.  Two  groups  were  treated  with  
hydroxylamine(NH2OH)  and  tris  solution  respectively  in  the  experiment.  Here  
hydroxylamine  was  applied  to  specifically  cleave  the  thioester  bond  and  a  tris  
solution  was  used  as  control.  Samples  collected  from  both  groups  were  further  
processed  using  gel  electrophoresis  and  western  immunoblotting.  Original  
lysates,  samples  from  hydroxylamine  treated  group  and  control  group  were  
loaded  on  the  same  gel.    
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Our  results  demonstrate  clear  evidence  that  Nav1.5  is  S-­palmitoylated  in  
HEK293  cells  (Figure  13).  The  western  blot  signal  in  the  ‘+’  (hydroxylamine  
treatment)  lane  indicates  the  thiol-­biotinylated  protein  component  captured  by  
streptavidin,  which  reflects  the  S-­palmitoylated  protein  before  hydroxylamine  
cleavage.  The  absence  of  signal  in  the  ‘-­’  (control)  lane  provides  confidence  that  
the  signal  in  the  ‘+’  lane  is  indeed  dependent  on  hydroxylamine  activity  and  
reflects  S-­palmitoylation.  Therefore,  the  presence  of  biotinylated  protein  in  
hydroxylamine  treatment  group  provides  us  strong  evidence  that  Nav1.5  is  
palmitoylated  in  the  HEK293  cells.  
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Figure  13.	  Nav1.5	  are  post-­translationally  modified  by  protein  palmitoylation  in  
HEK293  cells.  "+"  (hydroxylamine  treated  group)  indicates  the  existence  of  
protein  palmitoylation  on  Nav1.5  channels  and  "-­"  is  the  negative  control  group.  
All  the  biotinylated  proteins  (previously  palmitoylated  proteins)  were  
immunoprecipitated  using  a  streptavidin  pull  down  assay.  A  sodium  channel  pan  
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2.   Characterization  of  Nav1.5  palmitoylation  in  cardiac  tissues  using  
acyl  biotin  exchange  method  
Since  Nav1.5  is  predominately  expressed  in  the  cardiac  cells,  we  wanted  
to  further  investigate  whether  endogenous  Nav1.5  is  palmitoylated  in  cardiac  
myocytes.  Cardiac  tissues  from  adult  Sprague  Dawley  Rats  were  used  in  the  
experiment  to  identify  Nav1.5  palmitoylation  in  cardiac  tissues.  As  described  
previously,  the  signal  in  the  hydroxylamine  treatment  lane  indicates  Nav1.5  
palmitoylation  in  cardiac  tissues  (Figure  14A).  Caveolin,  which  has  been  
previously  reported  to  be  palmitoylated  in  cardiac  tissue(Dietzen,  Hastings  et  al.  
1995,  Tulloch,  Howie  et  al.  2011),  was  used  as  a  positive  control  (Figure  14C).  
Calmodulin,  which  does  not  contain  any  cysteine  residues,  was  used  as  a  
negative  control  and  shows  that  there  is  no  signal  for  non-­palmitoylated  proteins  
(Figure  14B).  These  results  provide  evidence  of  Nav1.5  palmitoylation  in  its  
native  expression  system.  
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Figure  14.  Identification  of  Nav1.5  palmitoylation  using  ABE  assay.  The  results  
are  representative  of  at  least  three  independent  experiments.  Left  lane  indicates  
total  input  lysate.  The  middle  lane  (NH2OH+)  indicates  palmitoylated  protein.  The  
right  lane  (NH2OH-­)  indicates  the  negative  control  group  treated  with  tris  solution.  
(A)  Nav1.5  is  palmitoylated  in  cardiac  tissues.  (B)  Calmodulin  is  present  but  not  
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3.   Characterization  of  Nav1.5  palmitoylation  using  metabolic  labelling  
assay  
Although  palmitoylation  is  the  most  common  acylation  modification  of  
proteins  in  mammalian  cells,  it  is  not  the  only  possible  modification  detected  by  
the  ABE  method.  As  a  direct  measure  of  Nav1.5  palmitoylation,  we  metabolically  
labeled  HEK293  cells  stably  expressing  Nav1.5  with  tritium  labeled  palmitate.  
Nav1.5  was  immunoprecipitated  and  palmitoylation  was  detected  by  
autoradiography  following  SDS-­PAGE.  The  same  set  of  samples  were  loaded  on  
another  gel  and  used  for  further  western  immunoblotting  analysis.  The  
autoradiography  film  cassette  was  stored  in  -­80°C  freezer  for  exposure  (up  to  
three  months).  Nav1.5  palmitoylation  was  shown  after  three  weeks  of  exposure  
(Figure  15A)  and  three  months  of  exposure  (Figure  16A).  Western  blot  analysis  
further  confirms  palmitoylated  Nav1.5  from  three  independent  experiments  
(Figure  15B,  16B).  These  experiments  demonstrated  that  tritium  labeled  palmitic  
acid  was  incorporated  into  Nav1.5  channels  as  identified  by  immunoprecipitation  
and  western  blot  analysis.  
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Figure  15.  Identification  of  Nav1.5  palmitoylation  in  HEK293  cells  using  metabolic  
tritium  labeling  (short  term  exposure).  (A)Scanned  image  of  film  developed  after  
three  weeks  of  exposure.  Tritium  labeled  palmitoylated  Nav1.5  was  detected  in  
HEK293  cells  stably  expressing  Nav1.5,  but  not  in  control  HEK293  cells;;  (B)  
Nav1.5  was  shown  in  Western  blot  analysis  using  the  same  samples;;  (C)  
comparable  amount  of  actin  from  the  same  samples  was  shown  in  Western  blot  
analysis.
A HEK293-           HEK293 
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Figure  16.  Identification  of  Nav1.5  palmitoylation  in  HEK293  cells  using  metabolic  
tritium  labeling  (long  term  exposure).  Samples  from  three  independent  ABE  
experiments  were  used  for  autoradiography  and  western  blot  analysis.  (A)  
Scanned  image  of  film  developed  after  three  months  of  exposure.  Tritium  labeled  
palmitoylated  Nav1.5  was  present  in  HEK293  cells  stably  expressing  Nav1.5.  As  
shown  in  this  figure,  long  term  exposure  also  increased  the  background  signal.  








Control  Nav1.5   Control   Nav1.5   Control   Nav1.5     
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4.   Characterization  of  Nav1.5  palmitoylation  using  click  chemistry  
assay  
We  were  also  able  to  detect  Nav1.5  palmitoylation  with  copper-­catalyzed  
click  chemistry  assay,  as  a  third  measurement  of  palmitoylation.  This  method  is  
based  on  metabolic  incorporation  of  alkynyl  derivatives  of  palmitic  acid  that  can  
be  detected  with  direct  in-­gel  fluorescence  analysis.    
In  the  experiment,  HEK293  cells  stably  expressing  Nav1.5  (Figure  16,  two  
lanes  on  the  right)  were  used  to  study  Nav1.5  palmitoylation  and  untransfected  
HEK293  cells  (Figure  17,  two  lanes  on  the  left)  were  used  as  negative  control.  
During  the  click  chemistry  experiment,  azide-­linked  reporter  tags  will  specifically  
label  the  previously  palmitoylated  proteins  for  fluorescence  visualization  in  later  
steps.    
Our  results  indicate  Nav1.5  is  palmitoylated  in  HEK293  cells.  Red  bands  
(Figure  17A)  indicating  palmitoylated  proteins  labeled  by  the  azide-­linked  reporter  
tags  after  click  chemistry  reaction.  Hydroxylamine  (shown  as  ‘+’  or  ‘-­’  in  the  
figure),  which  cleaves  the  thioester  bond,  was  used  at  the  final  step  to  
demonstrate  specificity  of  thioester-­dependent  labeling  and  protein  
palmitoylation.  The  absence  of  palmitoylation  signal  in  ‘+’  group  indicates  that  the  
azide-­activated  fluorescent  dye  which  previously  attached  to  the  palmitoylated  
site  was  removed  by  hydroxylamine  cleavage,  confirming  the  specificity  of  the  
fluorescence  signal  observed  in  ‘-­‘  group  (Figure  17A)  is  indeed  Nav1.5  
palmitoylation.  The  same  set  of  samples  used  for  fluorescence  visualization  were  
loaded  on  an  additional  gel  for  further  identification  using  gel  electrophoresis  and  
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western  blot  analysis  (Figure  17B).  These  results  demonstrate  Nav1.5  
palmitoylation  in  HEK293  cells.    
Altogether,  three  lines  of  biochemical  evidence  provide  sufficient  
confidence  to  conclude  that  Nav1.5  is  indeed  palmitoylated  in  both  the  
heterologous  expression  system  and  native  cardiac  tissue.  
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Figure  17.  Identification  of  cardiac  sodium  channel  palmitoylation  using  copper-­
catalyzed  click  chemistry.  The  results  are  representative  of  at  least  three  
independent  experiments.  The  first  and  second  lane  were  from  untransfected  
HEK293  cells  and  the  third  and  forth  lane  were  from  HEK293  cells  with  stable  
expression  of  Nav1.5.  (A)  In-­gel  fluorescence  analysis  of  protein  palmitoylation  
after  immunoprecipitation  of  Nav1.5  from  HEK293  cells  stably  expressing  
Nav1.5.  The  location  of  Nav1.5  protein  was  marked  by  the  arrows.  (B)  Western  
blot  analysis  of  the  samples  used  in  panel  A.  Nav1.5  was  detected  using  sodium  
channel  pan  antibody  in  both  hydroxylamine  treated  and  untreated  samples.  
Nav1.5  protein  was  not  expressed  in  untransfected  HEK293  samples.  
  
Control     Control     Nav1.5      Nav1.5
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B.   Bi-­directional  regulation  of  Nav1.5  palmitoylation  
To  determine  whether  Nav1.5  palmitoylation  can  be  regulated  in  living  
cells,  we  incubated  the  Nav1.5  stable  HEK293  cells  with  2-­Br-­palmitate,  a  
nonmetabolizable  palmitate  analog  that  is  broadly  used  as  a  inhibitor  of  
palmitoyltransferase.  2-­Br-­palmitite  can  irreversibly  inhibite  palmitoylation  and  
thus  leading  to  protein  depalmitoylation(Webb,  Hermida-­Matsumoto  et  al.  2000,  
Davda,  El  Azzouny  et  al.  2013).    Although  at  least  one  study  demonstrated  that  
2-­Br-­Palmitate  may  also  inhibit  acyl-­protein  thioesterase  activity  (Pedro,  Vilcaes  
et  al.  2013),  this  inhibition  is  not  predicted  to  be  appreciable  at  25  µM.    
We  treated  the  Nav1.5  stable  cells  with  various  concentrations  of  2-­Br-­
palmitate  for  24  hours  and  then  performed  the  ABE  assay.  Results  of  this  
experiment  indicate  that  2-­Br-­palmitate  can  eliminate  Nav1.5  palmitoylation  in  
HEK293  cells  at  concentrations  starting  from  25  µM  (Figure  18).    
By  introducing  extra  2-­Br-­palmitate  to  the  system,  we  increased  the  total  
amount  of  palmitic  lipid.  Therefore,  we  cannot  rule  out  the  possibility  that  the  
treatment  effect  was  induced  by  extra  palmitic  lipid  in  the  system.  Thus,  in  
another  set  of  experiments,  we  pre-­incubated  the  cells  with  palmitic  acid,  a  
palmitic  lipid  that  has  similar  structure  as  2-­Br-­palmitate.  Palmitic  acid  does  not  
inhibit  palmitoyltransferase,  but  rather  is  considered  as  a  substrate  for  
palmitoylation.  24  hours  treatment  of  palmitic  acid  was  predicted  to  increase  the  
substrate  for  palmitoylation.  Our  results  show  that  the  addition  of  palmitic  acid  
does  not  inhibit  palmitoylation.  Moreover,  it  was  able  to  substantially  enhance  
Nav1.5  palmitoylation  at  concentrations  as  low  as  10  µM  (Figure  18B).  Higher  
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concentration  of  palmitic  acid  also  increased  Nav1.5  palmitoylation  (data  not  
shown).  Therefore,  we  conclude  that  2-­Br-­palmitate  can  abolish  protein  
palmitoylation  by  inhibiting  palmitoyltransferase  enzymatic  activities  while  extra  
palmitic  acid  leads  to  the  enhancement  of  palmitoylation,  probably  due  the  
addition  of  palmitoylation  substrate  in  the  system.    
Overall,  these  data  demonstrate  that  the  two  distinct  forms  of  palmitate  
exert  opposite  effects  on  regulating  Nav1.5  protein  palmitoylation.  These  data  
confirm  that  Nav1.5  palmitoylation  is  subject  to  bidirectional  regulation  and  
provided  a  paradigm  that  we  took  advantage  of  to  study  how  site  specific  
palmitoylation  of  Nav1.5  modulates  the  biophysical  properties  of  the  channel.    
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Figure  18.  Palmitate  lipid  treatments  alter  Nav1.5  palmitoylation  in  HEK293  cells  
that  stably  express  Nav1.5.  The  results  are  representative  of  at  least  three  
independent  experiments.  (A)  2-­Br-­palmitate(2BP)  treatment  inhibited  Nav1.5  
palmitoylation  at  25µM.  (B)  Palmitic  acid(PA)  treatment  increased  Nav1.5  
palmitoylation  at  10µM.  
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C.   Palmitoylation  regulates  cardiac  excitability  
1.             Palmitoylation  alters  spontaneous  beating  activity  of  cardiomyocytes    
Cardiac  excitability  and  arrhythmia  generation  is  critically  dependent  on  
the  gating  of  multiple  ion  channel  proteins.  Recent  evidence  suggests  that  the  
activity  of  numerous  proteins,  including  ion  channels,  may  be  modulated  by  the  
palmitoylation,  one  of  the  most  common  post-­translational  lipid  modifications.  As  
we  already  showed  cardiac  sodium  channel  is  palmitoylated,  we  asked  if  
manipulating  protein  palmitoylation  in  cardiac  myocytes  would  alter  excitability.    
In  control  myocyte  cultures  we  routinely  observed  numerous  beating  cells  
on  each  coverslip  and  around  70%  of  the  myocytes  that  exhibited  inward  current  
in  voltage-­clamp  recordings  generated  spontaneous  action  potentials  in  current  
clamp  recordings  (Figure  19).  To  decrease  protein  palmitoylation,  we  incubated  
the  cells  with  2-­Br-­palmitate  (25µM).  After  24  hours  treatment  with  2-­Br-­palmitate,  
spontaneously  beating  myocytes  were  rarely  observed  and  none  of  the  cells  that  
exhibited  inward  sodium  current  in  voltage-­clamp  recordings  was  able  to  
generate  action  potentials  in  current  clamp  recordings  (Figure  19).  The  cells  were  
placed  at  resting  membrane  potential  in  our  experiment  settings,  however,  it  is  
still  possible  that  prolonged  hypoperolarization  may  restore  the  cardiomyocyte  
excitability  in  2-­Br-­palmitate  treatment  group.  In  contrast,  we  observed  distinct  
effects  when  myocytes  were  cultured  in  the  presence  of  additional  palmitate  acid  
(10µM),  the  primary  substrate  for  palmitoylation.  Our  biochemistry  data  indicates  
that  excess  palmitic  acid  can  enhance  Nav1.5  palmitoylation  (Figure  18).    In  
contrast  to  2-­Br-­palmitate  treatment,  palmitic  acid  did  not  abolish  beating  but  
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rather  many  cells  in  the  palmitic  acid  treated  group  displayed  spontaneous  
beating  and  action  potentials  were  readily  recorded  from  myocytes  in  this  
treatment  group.      
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Figure  19.  Palmitoylation  alters  cardiomyocytes  beating  activity.  Only  cells  that  
exhibited  inward  sodium  current  were  analyzed.  7  out  of  10  cells  (70%)  in  the  
control  group  fired  spontaneous  action  potentials.  None  of  the  10  cells  in  the  2-­
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2.   Palmitoylation  regulates  action  potential  duration  and  firing  
frequency  
   Since  palmitoylation  alters  cardiac  myocyte  spontaneous  beating  activity,  
we  further  asked  if  palmitoylation  could  also  affect  action  potential  activities.  Here  
we  only  compared  non-­treatment  group  and  palmitic  acid  treatment  group  since  
none  of  the  cells  in  2-­Br-­palmitiate  treatment  group  was  able  to  generate  an  
action  potential  in  our  experiments.  According  to  our  study,  the  recorded  action  
potentials  from  the  palmitic  acid  treatment  group  exhibited  an  increased  action  
potential  duration  (Figure  20A,  20B,  20C)  and  a  decreased  firing  frequency  
(Figure  20D)  compared  to  the  non-­treatment  group.  
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Figure  20.  Palmitoylation  regulates  cardiac  action  potential  duration  and  firing  
frequency.  (A)  Representative  action  potential  traces  of  cardiomyocytes  with  
(blue)  and  without  (black)  palmitic  acid  treatment.  Palmitic  acid(PA)  treatment  
increases  the  action  potential  duration.  (B)  Averaged  APD  measurements  (from  
the  beginning  of  depolarization  phase  to  the  end  of  repolarization  phase)  from  
the  spontaneous  firing  myocytes.  Averaged  APD  is  563ms  in  the  control  group  
and  890ms  in  the  palmitic  acid  treatment  group.  (C)  Averaged  APD  
measurements  of  single  action  potential  waveform  elicited  by  2  ms  stimulus  
pulses.  APD  is  330.4ms  in  the  non-­treatment  group  and  572.8ms  in  the  palmitic  
acid  treatment  group.  (D)  Firing  frequency  in  control  group  and  palmitic  acid  
treatment  group.  The  firing  frequency  is  1.2±0.10  in  the  control  group  and  
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3.   Palmitoylation  induces  early  after-­depolarization  like  phenomenon  
Interestingly,  when  comparing  the  spontaneous  action  potential  
waveforms,  we  often  observed  an  early  after-­depolarization  (Meadows  and  Isom)  
like  phenomenon  in  the  palmitic  acid  treatment  group  (Figure  21B,  21C),  but  not  
under  the  control  condition  (Figure  21A).  In  general,  EADs  occur  with  abnormal  
depolarization  during  action  potential  phase  2  or  phase  3,  and  are  identified  by  
the  presence  of  ectopic  action  potentials  before  normal  repolarization  is  
completed  (Zeng  and  Rudy  1995).  Unusual  openings  of  sodium  channels  is  one  
of  the  factors  that  contributes  to  the  generation  of  EADs.  EADs  can  result  in  
torsades  de  pointes,  tachycardia,  and  many  other  arrhythmias.  Our  data  suggest  
that  reducing  palmitoylation  in  cardiac  myocytes  attenuates  excitability  and  
enhancing  palmitoylation  (by  increasing  the  availability  of  substrate)  increases  
cardiomyocyte  excitability  and  may  enhance  risk  of  cardiac  arrhythmia  
generation.  
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Figure  21.  Spontanous  action  potential  recorded  from  non-­treatment  and  palmitic  
acid    treatment  group.  (A)  Cardiomyocyte  spontanous  action  potential  generated  
under  non-­treatment  condition.  The  action  potential  firing  occurs  at  a  constant  
rate  with  no  ectopic  firing  observed.  (B,C)  Action  potential  recorded  from  palmitic  
acid  treatment  group.  EAD  phenomenon  is  indicated  with  arrows.  The  results  are  
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D.   Palmitoylation  modulates  cardiac  myocyte  sodium  currents  
1.   Palmitoylation  does  not  alter  Nav1.5  fast  inactivation  in  
cardiomyocytes  
To  investigate  if  bidirectional  alterations  in  the  palmitoylation  of  cardiac  
sodium  channels  might  contribute  to  the  observed  changes  in  cardiomyocyte  
excitability,  we  examined  voltage-­gated  sodium  currents  in  the  cultured  
cardiomyocytes  from  neonatal  rats.  In  these  experiments,  we  blocked  potassium  
and  calcium  currents  in  order  to  record  isolated  voltage-­gated  sodium  currents.  
Cells  were  pre-­incubated  with  2-­Br-­palmitate  and  palmitic  acid,  respectively,  to  
study  the  effect  of  decreased  and  enhanced  palmitoylation.  Cells  were  held  at  -­
100mV  and  a  depolarizing  protocol  from  -­100mV  to  -­20mV  was  performed  to  
generate  the  isolated  sodium  currents.  Our  results  indicate  that  sodium  current  
recorded  from  neonatal  cardiomyocytes  activates  and  decays  rapidly,  and  that  
neither  2-­Br-­palmitate  nor  palmitic  acid  treatment  significantly  changed  the  rate  of  
sodium  current  fast  inactivation  in  myocytes  (Figure  22).
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Figure  22.  Normalized  Nav1.5  current  with  and  without  palmitate  lipid  treatment.  
All  data  are  shown  as  mean±s.e.m.  Data  from  the  24-­hour  pretreatment  of  2-­Br-­
palmitate  and  palmitic  acid  are  shown  in  green  and  blue,  respectively.  Black  lines  
indicate  data  from  the  control  condition.  Cells  were  depolarized  to  −20  mV  from  a  
holding  potential  of  −100  mV.  Inset  indicates  representative  family  of  traces  of  
Nav1.5  current  in  cardiomyocytes  evoked  with  depolarizations  ranging  from  -­80  
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2.   Palmitoylation  does  not  alter  Nav1.5  current  densities  in  
cardiomyocytes  
To  study  whether  palmitoylation  alters  Nav1.5  protein  expression  at  cell  
surface,  we  compared  the  sodium  peak  current  in  different  treatment  groups.  
Sodium  currents  were  generated  using  a  depolarizing  protocol  from  -­100mV  to  -­
20mV.  Our  results  indicate  there  is  no  significant  difference  of  cell  size  (Figure  
24,  p>0.05,  unpaired  Student’s  t-­test)    or  current  density  among  untreated  cells,  
2Br-­palmitate  treated  cells  and  palmitic  acid  treated  cells  (Figure  23,  p>0.05,  
unpaired  Student’s  t-­test),  suggesting  palmitoylation  might  not  play  a  major  role  
in  regulating  cardiac  sodium  channel  surface  expression.    
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Figure  23.  Comparison  of  normalized  current  density.  Current  density  was  
measured  as  the  peak  current  divided  by  cell  capacitance  (nA/pF).  Box  and  
Whisker  plots  were  generated  to  compare  the  mean  difference.  The  box  was  
drawn  from  the  25th  to  75th  percentiles.  Tukey  analysis  was  used  to  determine  
the  outliers  (shown  as  individual  points  above  the  whiskers).  In  the  non-­treatment  
group,  mean  current  density  is  0.43±0.04  nA/pF,n=35;;  In  the  2-­Br-­palmitate  
treated  group,  mean  current  density  is  0.30±0.08  nA/pF,n=16.  In  the  palmitic  acid  
treatment  group,  the  current  density  is  0.56±0.10  nA/pF,n=13.  No  significant  
statistical  difference  is  observed  in  2-­Br-­palmitate  group  (p=0.13,  unpaired  
Student’s  t-­test)  or  palmitic  acid  group  (p=0.18,  unpaired  Student’s  t-­test)
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Figure  24.  Comparison  of  cardiomyocyte  size.  Cell  size  was  measured  by  cell  
capacitance  (pF).  Box  and  Whisker  plots  were  used  to  compare  the  difference  in  
mean.  The  box  was  drawn  from  the  25th  to  75th  percentiles.  Tukey  analysis  was  
used  to  determine  the  outliers  (shown  as  individual  points  above  the  whiskers).  In  
the  non-­treatment  group,  mean  cell  size  is  14.75±0.84  pF;;  In  the  2-­Br-­palmitate  
treated  group,  mean  cell  size  is  18.48±2.15  pF.  In  the  palmitic  acid  treatment  
















   83  
3.       Palmitoylation  alters  persistent  current  of  Nav1.5  in  cardiomyocytes  
In  excitable  cells,  the  transient  sodium  currents  activate  and  inactivate  
rapidly,  initiating  action  potentials,  helping  regulate  the  duration  of  the  action  
potential  waveform  and  modulating  the  frequency  of  action  potential  firing  
activities.  However,  there  is  a  small  sustained  component  of  sodium  current  
called  persistent  current(or  late  sodium  current)  that  fails  to  inactivate  
rapidly(Kiss  2008).  Persistent  current  generally  consists  of  less  than  5%  of  peak  
sodium  currents.  However,  it  has  profound  influence  on  cell  excitability  under  
both  physiological  and  pathological  conditions.    
Previous  studies  show  that  persistent  sodium  current  can  contribute  to  
repetitive  firing  of  neuronal  action  potential(Harvey,  Li  et  al.  2006,  Stafstrom  
2011).  And  enhanced  persistent  currents  of  sodium  channels  induced  by  
inherited  mutation  or  acquired  channel  dysfunction  in  the  central  nervous  system  
is  associated  with  epilepsy  generation  (Stafstrom  2007).  In  addition,  Nav1.5  
persistent  currents  can  substantially  contribute  to  sodium  overloading  in  
myocytes  and  potential  cardiac  arrhythmia  generation(Saint  2008).  
Since  persistent  current  plays  an  important  role  in  cellular  excitability,  we  
further  investigated  whether  regulation  of  palmitoylation  can  mediate  the  
persistent  current  component  of  Nav1.5.  Our  results  demonstrate  palmitic  acid  
treatment,  which  enhances  palmitoylation  of  cardiac  sodium  channels,  induces  a  
four-­fold  increase  in  the  persistent(non-­inactivating)  component  of  the  total  
sodium  currents  (Figure  25).  Although  the  magnitude  of  the  inward  persistent  
current  was  slightly  less  than  1%  of  the  peak  current  after  palmitic  acid  treatment,  
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this  increase  is  similar  to  that  observed  with  several  long-­QT3  
mutations(Bankston,  Yue  et  al.  2007).  An  increase  in  these  small  but  powerful  
late  currents  is  likely  to  contribute  to  the  prolonged  APD  and  EAD  like  
phenomenon  shown  in  Figure  21.    Therefore,  the  enhanced  persistent  current  
induced  by  Nav1.5  palmitoylation  may  partially  account  for  the  altered  excitability  
in  cardiomyocytes.
   85  
  
Figure  25.  Persistent  current  (A)  and  statistical  analysis  (B)  comparing  the  control  
condition  and  treatment  groups  in  neonatal  cardiomyocytes.  The  persistent  
current  was  measured  as  the  percentage  of  peak  current.  The  persistent  current  
is  0.19±  0.16%  (control,  black);;  0.04±0.30%  (2-­Br-­palmitate,  green);;  
0.83±0.24%(palmitic  acid,  blue).  n=10.  The  difference  between  control  group  and  
palmitic  acid  treatment  group  is  statistically  significant  (p=0.037).
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4.       Palmitoylation  affects  Nav1.5  voltage  dependence  of  inactivation  in  
cardiomyocytes  
I  also  studied  how  palmitoylation  affects  Nav1.5  voltage  dependence  of  
activation  and  inactivation.  Palmitic  acid  treatment  substantially  shifted  the  
steady-­state  inactivation  to  more  depolarized  voltages  (Figure  26B),  which  would  
largely  increase  channel  availability  under  depolarized  membrane  potentials  and  
lead  to  the  enhanced  ‘window  current’.  It  is  likely  one  of  the  factors  that  
contributes  to  enhanced  excitability  of  cardiomyocytes.    
In  contrast,  2-­Br-­palmitate  induced  a  hyperpolarizing  shift  of  steady-­state  
inactivation  (Figure  26A).  The  parameters  of  activation  and  inactivation  curves,  
obtained  from  Boltzmann  equation  fits,  are  summarized  in  Table  7.  While  palmitic  
acid  treatment  induced  biophysical  changes  in  sodium  current  properties  that  
would  increase  electrical  activity  in  myocytes,  the  large  negative  shift  (around  
20mV)  in  the  voltage-­dependence  of  inactivation  observed  with  2-­Br-­palmitate  is  
predicted  to  effectively  reduce  channel  availability  as  well  as  cardiomyocyte  
excitability.    
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Figure  26.  Comparison  of  sodium  channel  voltage  dependence  of  activation  and  
steady-­state  inactivation  in  neonatal  cardiomyocytes.  Black  curve  and  open  
symbol  indicates  non-­treatment  group.  Green  indicates  2-­Br-­palmitic  treatment  
group.  Blue  indicates  palmitic  acid  treatment  group.      
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5.       Palmitoylation  affects  Nav1.5  recovery  from  inactivation  in  
cardiomyocytes  
As  discussed  in  previous  sections,  sodium  channels  typically  come  to  a  
refractory  period  after  opening,  which  allows  sodium  channels  to  recover  from  
inactivation  and  prevent  them  from  repetitive  opening  during  short  time  period.  
This  mechanism  is  an  important  factor  to  maintain  normal  action  potential  
activities.  Altered  recovery  of  Nav1.5  may  disrupt  cell  excitability  and  increase  
the  risk  of  cardiac  arrhythmia.    
To  assess  how  palmitoylation  affects  Nav1.5  recovery  from  inactivation,  
we  depolarized  the  cells  to  +20mV  and  studied  the  time  course  that  sodium  
currents  recovered  from  inactivation  during  a  varying  time  period.  Sodium  
channel  recovery  were  examined  under  two  time  scales,  0-­50  ms  and  0-­2048  
ms.  Our  results  demonstrate  that  palmitic  acid  enhanced  recovery  from  
inactivation  in  cardiomyocytes  while  2-­Br-­palmitate  largely  slowed  the  recovery  
from  inactivation  (Figure  27).  Therefore,  the  regulation  of  recovery  rate  by  
palmitoylation  could  also  contribute  to  the  altered  myocyte  excitability  under  
different  treatment  conditions.    
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Figure  27.  Comparison  of  sodium  channel  recovery  from  inactivation  among  non-­
treatment  group  (black  curve  and  open  symbol),  2-­Br-­palmitate  (green  and  solid  
symbol)  and  palmitic  acid  treatment  (blue  curve  and  solid  symbol).  The  recovery  
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E.   Palmitoylation  alters  Nav1.5  properties  in  HEK  293  cells    
1.   Palmitoylation  does  not  alter  Nav1.5  fast  inactivation  in  HEK  293  
cells  
In  order  to  explore  the  mechanism  by  which  palmitoylation  regulates  
cardiomyocyte  sodium  currents,  we  investigated  whether  modulation  of  
palmitoylation  alters  the  functional  properties  of  Nav1.5  channels  expressed  in  
HEK293  cells.  The  main  advantage  of  these  cells  is  that  they  do  not  express  
significant  levels  of  other  ion  channels  and  can  be  readily  used  to  express  
recombinant  Nav1.5  channels  in  isolation.    
We  incubated  the  HEK293  cells  expressing  Nav1.5  with  25  µM  2-­Br-­
palmitate  for  24  hours  and  performed  whole-­cell  electrophysiological  recordings.  
Sodium  currents  were  generated  by  a  depolarizing  potential  to  -­20mV  from  a  
holding  potential  of  -­100mV.  The  rate  of  fast  inactivation  was  not  significantly  
altered  by  2-­Br-­palmitate  (Figure  28A)  or  palmitic  acid  (Figure  28B)  compared  to  
the  control  group.  Representative  current  traces  and  current-­voltage  plots  under  
all  three  treatment  conditions  are  shown  in  Figure  29.    
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Figure  28.  Normalized  currents  of  Nav1.5  compared  with  2-­Br-­palmitate  and  
palmitic  acid  treatments.  Channels  were  depolarized  to  −20  mV  from  a  holding  
potential  of  −100  mV.  2-­Br-­palmitate  treatment  group  data  are  shown  in  green  
and  palmitic  acid  treatment  group  data  are  shown  in  blue.  Control  conditions  are  
shown  in  black.  Data  were  averaged  from  11  sodium  current  measurements.    
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Figure  29.  Representative  current  traces  and  normalized  current-­voltage  (IV)  
plot.  Left:  control;;  Middle:  2-­Br-­palmitate  treatment;;  Right:  palmitic  acid  treatment.  
Top  panel  shows  the  representative  normalized  current  traces  and  the  bottom  
panel  shows  the  corresponding  IV  curves  (n=10,  all  data  points  are  shown  as  
mean±s.e.m.).  Sodium  currents  were  evoked  by  voltage  steps  from  −100  to  +45  
mV  with  5-­mV  increments  (ΔV)  from  a  holding  potential  of  −100  mV.  
   93  
2.   Palmitoylation  regulates  Nav1.5  voltage-­dependence  of  inactivation  
in  HEK  293  cells  
In  addition  to  sodium  current  kinetics,  we  also  studied  how  palmitoylation  
regulates  Nav1.5  voltage  dependence  of  activation  and  inactivation  in  HEK293  
cells.  Sodium  currents  were  elicited  by  voltage  steps  from  −100  to  +45  mV  with  5  
mV  increments  (ΔV)  from  a  holding  potential  of  −100  mV.  The  normalized  current  
conductance  was  plotted  versus  depolarization  voltage.  In  order  to  evaluate  
steady-­state  inactivation,  cells  were  held  at  -­100  mV  and  then  stepped  to  a  
500ms  inactivating  prepulse  from  -­150  mV  to  -­10  mV  with  10  mV  increments.  
The  channels  that  remain  available  after  each  inactivating  prepulse  were  
evaluated  by  the  peak  current  produced  during  a  20  ms  test  pulse  at  0  mV.    
Our  results  revealed  that  2-­Br-­palmitate  treatment  substantially  shifted  the  
steady-­state  inactivation  of  wild-­type  (wt)  Nav1.5  to  more  hyperpolarized  voltages  
(Figure  30A).  By  contrast  palmitic  acid,  which  enhances  Nav1.5  palmitoylation  in  
HEK293  cells,  shifted  the  voltage-­dependence  of  steady-­state  inactivation  in  the  
depolarizing  direction,  enhancing  channel  availability  (Figure  30B).  These  effects  
were  also  observed  with  shorter  duration  (4  hr)  2-­Br-­palmitate  treatments  (Figure  
31).  The  midpoint  of  the  inactivation  and  activation  curves  are  summarized  in  
Table  7.  
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Figure  30.  Palmitoylation  alters  voltage  dependence  of  activation  and  
inactivation.  2-­Br-­palmitate  treatment  group  data  are  shown  in  green  and  palmitic  
acid  treatment  group  data  are  shown  in  blue.  Control  conditions  are  shown  in  
black  lines  and  open  symbols.  All  data  are  shown  as  mean±s.e.m.  (A)  2-­Br-­
palmitate  treatment  shifts  steady-­state  inactivation  to  hyperpolarized  voltages,  
without  changing  the  voltage  dependence  of  activation.  (B)  palmitic  acid  
treatment  shifts  both  voltage  dependence  of  activation  and  inactivation  in  the  
depolarized  direction.    
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Figure  31.  2-­Br-­Palmitate  effects  on  Nav1.5  biophysical  properties.  All  data  
points  are  shown  as  mean±s.e.m.  Green  lines  and  symbols  indicate  2-­Br-­
Palmitate  (2BP)  treatment  (solid  lines  show  4  hours  treatment  and  dashed  lines  
show  24  hours  treatment)  and  black  lines  and  symbols  indicates  no  treatment  
involved.  (A)  Both  24  hours  and  4  hours  treatment  significantly  shift  Nav1.5  
steady-­state  inactivation.  There  is  no  significant  difference  between  24  hours  and  
4  hours  treatment.  (B)  Both  24  hours  and  4  hours  treatment  alter  recovery  from  
inactivation  
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3.   Palmitoylation  alters  Nav1.5  recovery  from  inactivation  in  HEK  293  
cells  
In  addition  to  the  alteration  in  steady-­state  inactivation,  2-­Br-­palmitate  
treatment  slightly  slowed  the  rate  for  recovery  from  inactivation  (Figure  32A).  By  
contrast  palmitic  acid,  which  enhances  Nav1.5  palmitoylation  in  HEK293  cells,  
increased  the  rate  of  recovery  from  inactivation  (Figure  32B).    
Overall,  our  data  suggest  that  depalmitoylation  induces  a  hyperpolarized  
shift  on  sodium  channel  voltage  dependence  of  inactivation  in  HEK293  cells.  On  
the  other  hand,  enhanced  palmitoylation  induces  a  depolarized  shift  on  voltage  
dependence  of  inactivation  and  speeds  the  rate  of  recovery  from  fast  inactivation.  
These  results  are  consistent  with  our  findings  from  neonatal  cardiomyocytes,  
indicating  palmitoylation  effects  on  Nav1.5  are  likely  conserved  in  different  
expression  systems  and  confirming  HEK293  as  a  valid  expression  system  for  
further  studies  on  Nav1.5  palmitoylation.  
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Figure  32.  Palmitoylation  alter  Nav1.5  recovery  from  inactivation.  (A)  2-­Br-­
palmitate  treatment  (green)  slightly  slowed  the  recovery  from  inactivation.  (B)  
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4.   Palmitoylation  does  not  alter  Nav1.5  slow  inactivation  or  recovery  
from  slow  inactivation  
Sodium  channel  inactivation  is  a  biophysical  process  that  prevents  
channel  conductance  in  response  to  the  membrane  depolarization  (Goldin  2003).  
The  time  course  of  sodium  channel  inactivation  is  dependent  on  the  duration  of  
depolarization.  Inactivation  that  occurs  within  a  millisecond  to  tens  of  
milliseconds  time  frame  is  referred  to  as  fast  inactivation.  However,  longer  forms  
of  inactivation  (slow  inactivation)  could  also  occur  in  response  to  prolonged  
depolarization,  taking  from  hundreds  of  milliseconds  to  tens  of  seconds(Vilin  and  
Ruben  2001).  Slow  inactivation  is  an  important  regulator  of  the  availability  of  
cardiac  sodium  channels  for  activation.  Many  mutations  of  Nav1.5  that  
associated  with  cardiac  arrhythmia  diseases  exhibit  altered  slow  inactivation  
(Ulbricht  2005).  Therefore,  we  would  like  to  explore  the  effects  of  palmitoylation  
on  slow  inactivation  of  Nav1.5.    
The  voltage  clamp  protocol  for  slow  inactivation  and  recovery  from  slow  
inactivation  is  shown  in  Figure  31.  To  study  the  voltage  dependence  of  slow  
inactivation,  a  10s  or  30s  pre-­pulse  ranging  from  -­150mV  to  +10mV  with  a  10mV  
interval  was  applied  to  the  cells  from  a  holding  potential  at  -­130mV.  Channel  
availability  was  measured  with  a  following  depolarizing  pulse  at  -­10mV.  To  study  
the  recovery  from  slow  inactivation,  cells  were  depolarized  to  0mV  to  fully  
inactivate  sodium  channels  and  then  held  at  -­130mV  for  50ms  to  2000ms  
recovery  time.  Channels  recovered  from  inactivation  were  measured  using  a  
50ms  depolarizing  pulse  at  -­10mV.  From  our  results,  neither  2-­Br-­palmitate  nor  
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palmitic  acid  seems  to  affect  the  Nav1.5  voltage  dependence  of  slow  inactivation  
or  recovery  from  slow  inactivation  (Figure  33).  
The  above  experiment  results  confirm  that  Nav1.5  current  properties  are  
indeed  regulated  by  modulating  palmitoylation  and  that  the  HEK293  heterologous  
expression  system  serves  as  a  model  system  to  further  explore  the  molecular  
determinants  for  this  regulation.      
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Figure  33.  Palmitoylation  does  not  affect  Nav1.5  slow  inactivation  or  recovery  
from  slow  inactivation.  Black  and  open  symbol  indicates  control  group.  Blue  
indicates  palmitic  acid  treatment  and  green  indicates  2-­Br-­palmitate  treatment.    
(A,B)  The  duration  of  pre-­conditioning  pulse  was  set  at  10s.  (C,D)  The  duration  of  
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F.   Computer  simulation  of  Nav1.5  palmitoylation  and  alteration  in    
myocyte  excitability  
Our  previous  experimental  results  suggest  that  palmitoylation  of  Nav1.5  in  
cardiac  myocytes  regulates  cardiac  excitability  through  manipulating  Nav1.5  
biophysical  properties.  However,  we  cannot  rule  out  the  possibility  that  
palmitoylation  of  other  proteins  in  cardiac  myocyte  could  also  contribute  to  the  
altered  excitability.    
To  assess  if  the  observed  changes  in  sodium  channel  activity  might  
indeed  be  sufficient  to  account  for  the  changes  in  cardiomyocyte  excitability  
shown  in  Figures  19,  20  and  21,  we  replicated  the  2-­Br-­palmitate  and  palmitic  
acid  induced  changes  in  Nav1.5  in  a  computational  model  of  a  human  myocyte  
and  assessed  the  impact  on  action  potential  generation.  The  computational  
model,  previously  implemented  in  the  NEURON  simulation  environment(Hines  
and  Carnevale  1997),  was  minimally  adjusted  (Figure  34).  The  consequences  of  
increased  palmitoylation  (palmitic  acid  treatment)  were  simulated  by  shifting  the  
voltage-­dependence  of  inactivation  by  5  mV  in  the  positive  direction  and  
increasing  the  non-­inactivating  component  by  approximately  4-­fold  (Figure  
35B,C).  The  consequences  of  Nav1.5  depalmitoylation  were  simulated  by  shifting  
the  voltage-­dependence  of  inactivation  24  mV  in  the  negative  direction  and  
slightly  decreasing  the  non-­inactivating  component  (Figure  35B,C).  In  the  model  
myocyte,  the  simulated  sodium  currents  with  enhanced  palmitoylation  
substantially  increased  the  action  potential  duration  (Figure  35D).  On  the  
contrary,  when  we  simulated  the  effects  of  sodium  channel  depalmitoylation,  the  
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model  myocyte  completely  failed  to  generate  action  potentials,  consistent  with  
our  finding  in  cultured  cardiomyocytes  (Figure  19).  This  indicates  the  changes  in  
cardiac  sodium  channel  activity  due  to  alterations  in  palmitoylation  are  sufficient  
to  generate  the  altered  excitability  that  we  observed  from  the  treatment  group  in  
primary  myocyte  studies.  The  detailed  transition  rate  expressions  for  the  model  
are  summarized  in  Table  5.
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Figure  34.  Diagram  of  Markov  model  (a  mathematical  model  developed  to  
describe  the  stochastic  behavior  of  single  ion  channels)  used  for  computer  
simulation  of  voltage-­gated  sodium  channel  conductances.    C1-­C3,  closed  (non-­
conducting)  states;;  O,  open  (conducting)  state;;  I1-­I4,  fast-­inactivated  (non-­
conducting)  states;;  SI,  slow-­inactivated  (non-­conducting)  state.  Forward  and  
reverse  transitions  are  indicated  and  transition  rate  expressions  are  provided  in  
table  5.
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Transition   Nav1.5  control  conditions   PA  treatment   2BP  treatment  
α01   -­3*0.32*(v+47.13)/(exp(-­0.1*(v+47.13))-­1)     unchanged     unchanged  
β01   0.08  *  exp(-­(v)/11)     unchanged     unchanged  
α02   -­2*0.32*(v+47.13)/(exp(-­0.1*(v+47.13))-­1)     unchanged     unchanged  
β02   2  *  (0.08  *  exp(-­(v)/11))     unchanged     unchanged  
α03   -­0.32*(v+47.13)/(exp(-­0.1*(v+47.13))-­1)     unchanged     unchanged  
β03   3  *  (0.08  *  exp(-­(v)/11))     unchanged     unchanged  
α11   -­3*0.32*(v+47.13)/(exp(-­0.1*(v+47.13))-­1)     unchanged     unchanged  
β11   0.08  *  exp(-­(v)/11)     unchanged     unchanged  
α12   -­2*0.32*(v+47.13)/(exp(-­0.1*(v+47.13))-­1)     unchanged     unchanged  
β12   2  *  (0.08  *  exp(-­(v)/11))     unchanged     unchanged  
α13   -­0.32*(v+47.13)/(exp(-­0.1*(v+47.13))-­1)     unchanged     unchanged  
β13   3  *  (0.08  *  exp(-­(v)/11))     unchanged     unchanged  







βi1   (0.135*exp(-­0.147*(v+80)))   unchanged   unchanged  







βi2   (0.135*exp(-­0.147*(v+80)))   unchanged   unchanged  
αi3   (1/(0.13*(1+(exp(-­1*(v+10.66)/11.1)))))   unchanged   unchanged  
βi3   (0.135*exp(-­0.147*(v+80)))   unchanged   unchanged  
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αi4   (1/(0.13*(1+(exp(-­1*(v+10.66)/11.1)))))   unchanged   unchanged  







αsi   0.00321     unchanged     unchanged  
βsi   (.0037933*0.00001)*exp(-­(v)/7.7)     unchanged     unchanged  
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Figure  35.  Computer  simulations  illustrate  the  impact  of  depalmitoylation  versus  
enhanced  palmitoylation  on  cardiomyocyte  excitability.  (A)  Comparison  of  peak  
simulated  control  Nav1.5,  2-­Br-­palmitate  and  palmitic  acid  “treated”  currents  
elicited  by  a  step  depolarization  to  -­20  mV.    In  the  simulation,  the  kinetics  of  
activation  and  open-­channel  inactivation  were  not  altered  under  the  three  
conditions.  The  current  densities  were  set  to  be  equal  to  the  peak  control  current  
density  for  comparison  of  kinetic  differences.  (B)  Comparison  of  persistent  (or  so-­
called  late)  Nav1.5  currents  for  the  three  simulated  conditions.  (C)  Comparison  of  
voltage-­dependence  of  steady-­state  inactivation  for  control  Nav1.5  (black  lines  
and  open  symbols),  2-­Br-­palmitate  (green  lines  and  symbols)  and  palmitic  acid  
(blue  lines  and  symbols)  “treated”  currents.    (D)  Simulated  action  potentials  from  
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these  simulations  and  the  second  and  third  action  potentials  are  shown.  The  
black  trace  shows  action  potentials  with  the  control  Nav1.5  channels,  the  green  
trace  with  Nav1.5  channels  modeled  to  reflect  the  changes  induced  by  
depalmitoylation  with  2-­Br-­palmitate  and  the  blue  trace  with  Nav1.5  channels  
modeled  to  reflect  the  changes  induced  by  enhanced  palmitoylation  with  palmitic  
acid  treatment.
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G.   Identification  of  palmitoylation  sites    
1.   Prediction  of  potential  palmitoylation  sites  using  bioinformatics  tools  
In  order  to  determine  how  Nav1.5  activities  are  regulated  by  
palmitoylation,  we  interrogated  the  channel  sequence  for  potential  post-­
translational  modification  sites.  Although  no  single  conserved  sequence  of  
palmitoylation  has  been  identified,  the  bioinformatics  tool  CSS-­Palm  3.0  can  
predict  which  cysteines  are  potential  palmitoylation  sites(Zhou,  Xue  et  al.  2006).  
By  comparing  the  similarity  of  amino  acid  sequence  surrounding  cysteines  with  
previously  determined  palmitoylation  sites,  the  entire  Nav1.5  sequence  was  
analyzed  and  four  endogenous  intracellular  cysteine  residues  that  are  highly  
predicted  to  be  palmitoylated  were  identified  (Figure  36A,  Table  6).  These  four  
cysteines  are  located  in  the  cytoplasmic  linker  between  domains  II  and  III  and  
three  out  of  four  residues  form  a  cysteine  cluster  (Figure  36B).    
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Figure  36.  Identification  of  potential  palmitoylation  sites  using  CSS-­palm  3.0.  (A)  
Position  and  sequence  of  the  potential  endogenous  sites  that  are  predicted  by  
the  bioinformatics  tool  CSS-­palm  3.0  with  high  threshold.  (B)  Schematic  view  of  
the  localization  of  four  predicted  endogenous  palmitoylation  sites.  All  four  
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Table  6.  The  score  matrix  of  the  palmitoylation  prediction  results  from  CSS-­PALM  
3.0.    
The   predicted   palmitoylation   sites   (C981,  C1176,  C1178,  C1179)   are   indicated  
with   red   colored   text.   Any   cysteine   site   with   a   score   that   is   larger   than   the  
corresponding   cutoff   value   is   considered  as  a  potential   palmitoylation   site.  The  
high  threshold  setting  of  CSS-­PALM  was  used  for  the  prediction  cutoff.  
  
Position   Peptide   Score   Cutoff   Cluster  
139   LFNMLIMCTILTNCV   0.286   0.308   Cluster  A  
145   MCTILTNCVFMAQHD   0.454   0.497   Cluster  B  
182   KILARGFCLHAFTFL   0.167   0.308   Cluster  A  
260   VMVLTVFCLSVFALI   0.124   0.308   Cluster  A  
280   MGNLRHKCVRNFTAL   0.339   1.225   Cluster  C  
326   GTSDVLLCGNSSDAG   0.281   0.308   Cluster  A  
335   NSSDAGTCPEGYRCL   0.769   1.225   Cluster  C  
341   TCPEGYRCLKAGENP   0.364   1.225   Cluster  C  
373   FRLMTQDCWERLYQQ   0.167   0.497   Cluster  B  
489   MSSGTEECGEDRLPK   0.167   0.308   Cluster  A  
597   KKNSTVDCNGVVSLL   0.934   1.225   Cluster  C  
649   MLTSQAPCVDGFEEP   0.119   0.308   Cluster  A  
683   LEESRHKCPPCWNRL   0.194   0.497   Cluster  B  
686   SRHKCPPCWNRLAQR   0.306   0.497   Cluster  B  
699   QRYLIWECCPLWMSI   0.554   1.225   Cluster  C  
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700   RYLIWECCPLWMSIK   1.116   1.225   Cluster  C  
726   TDLTITMCIVLNTLF   0.727   1.225   Cluster  C  
896   LIIFRILCGEWIETM   0.014   0.308   Cluster  A  
906   WIETMWDCMEVSGQS   0.11   0.308   Cluster  A  
915   EVSGQSLCLLVFLLV   1.198   1.225   Cluster  C  
981   KRTTWDFCCGLLRQR   1.083   0.497   Cluster  B  
982   RTTWDFCCGLLRQRP   1.14   1.225   Cluster  C  
1004   AQGQLPSCIATPYSP   0.372   1.225   Cluster  C  
1046   PGDPEPVCVPIAVAE   0.306   1.225   Cluster  C  
1128   AEPQAPGCGETPEDS   0.289   1.225   Cluster  C  
1136   GETPEDSCSEGSTAD   0.537   1.225   Cluster  C  
1167   DVKDPEDCFTEGCVR   0.033   0.308   Cluster  A  
1172   EDCFTEGCVRRCPCC   0.12   0.497   Cluster  B  
1176   TEGCVRRCPCCAVDT   0.806   0.497   Cluster  B  
1178   GCVRRCPCCAVDTTQ   0.333   0.308   Cluster  A  
1179   CVRRCPCCAVDTTQA   0.75   0.497   Cluster  B  
1198   WWRLRKTCYHIVEHS   0.306   1.225   Cluster  C  
1272   KYFTNAWCWLDFLIV   0.496   1.225   Cluster  C  
1341   IMNVLLVCLIFWLIF   0.11   0.308   Cluster  A  
1363   FAGKFGRCINQTEGD   0.25   0.497   Cluster  B  
1384   IVNNKSQCESLNLTG   0   0.308   Cluster  A  
1539   VTIMFLICLNMVTMM   0.727   1.225   Cluster  C  
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1575   VAIFTGECIVKLAAL   0.694   1.225   Cluster  C  
1703   TFANSMLCLFQITTS   0.09   0.308   Cluster  A  
1728   LNTGPPYCDPTLPNS   0.223   1.225   Cluster  C  
1742   SNGSRGDCGSPAVGI   0.488   1.225   Cluster  C  
1850   VSGDRIHCMDILFAF   0.471   1.225   Cluster  C  
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2.   Biophysical  and  biochemical  characterization  of  potential  
palmitoylation  sites  
To  further  investigate  the  functional  role  of  these  four  endogenous  
cysteines  in  regulating  channel  palmitoylation,  we  constructed  a  mutant  channel  
with  these  four  cysteine  residues  substituted  to  alanine  residues  using  site-­
directed  mutagenesis  in  an  attempt  to  eliminate  endogenous  palmitoylation.  This  
mutant  channel  construct,  referred  to  as  Nav1.5-­AAAA,  was  used  in  experiments  
described  below.    
To  assess  the  functional  role  of  the  four  predicted  endogenous  
palmitoylation  sites,  we  transiently  transfected  the  Nav1.5-­AAAA  channel  into  
HEK293T  cells  and  subsequently  treated  the  cells  with  2-­Br-­palmitate.  The  
results  demonstrate  that  2-­Br-­palmitate  does  not  alter  Nav1.5-­AAAA  fast  
inactivation  significantly  (Figure  37A,  right).  Wild-­type  Nav1.5  was  transiently  
transfected  into  a  second  set  of  cells  as  a  control.  Treatment  with  2-­Br-­palmitate  
shifted  the  steady-­state  inactivation  of  transiently  transfected  wt  Nav1.5  in  the  
hyperpolarized  direction  (Figure  37B  left),  similar  to  that  previously  observed  with  
the  Nav1.5  stable  cell  line.  Interestingly,  although  chemical  inhibition  of  
palmitoylation  still  shifted  steady-­state  inactivation  of  Nav1.5-­AAAA  in  the  
hyperpolarized  direction  (Figure  37B,  right  panel  Table  7),  the  effect  was  
substantially  smaller  (<3  mV)  compared  with  wt  Nav1.5  (~17  mV).  The  differential  
effect  implies  that  one  or  more  of  these  four  cysteines  are  crucial  in  the  
regulation  of  Nav1.5  by  palmitoylation.  In  addition,  we  found  that  the  midpoint  
(V½)  of  Nav1.5-­AAAA  steady-­state  inactivation  under  control  conditions  was  
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quite  close  to  that  of  wt  Nav1.5  after  2-­Br-­palmitate  treatment,  leading  us  to  
conclude  that  the  cysteine  to  alanine  substitution(s)  alter  steady-­state  
inactivation,  probably  through  regulation  of  palmitoylation  on  one  or  more  of  the  
four  predicted  cysteines.  To  confirm  that  the  ablation  of  2-­Br-­palmitate’s  effect  is  
due  to  the  alteration  in  palmitoylation  status,  we  used  the  ABE  assay  to  assess  
palmitoylation  of  wt  Nav1.5  and  Nav1.5-­AAAA  channels.  Our  results  indicate  that  
the  substitution  of  cysteine  residues  to  alanine  residues  largely  reduced  the  
palmitoylation  of  the  channel  (Figure  38).  These  data  strongly  support  the  
hypothesis  that  palmitoylation  induced  changes  in  Nav1.5  function  is  produced  
by  specific  modification  of  one  or  more  of  these  four  endogenous  cysteine  
residues.  
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Figure  37.  Effects  of  chemical  inhibition  of  palmitoylation  on  the  biophysical  
properties  of  wild-­type  Nav1.5  and  Nav1.5-­AAAA.  Black  lines  and  open  symbols  
indicate  data  from  control  conditions  and  green  indicates  data  from  the  2-­Br-­
palmitate  (2BP)  treatment  group.  (A)  Normalized  currents  from  cells  transfected  
with  Nav1.5  (left)  and  Nav1.5-­AAAA  with  and  without  2BP  treatment.  (B)  
Comparison  of  wild-­type  Nav1.5  (left)  and  Nav1.5-­AAAA  channel  voltage-­
dependence  of  activation  and  steady-­state  inactivation  before  (black)  and  after  
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Figure  38.  Characterization  of  Nav1.5  AAAA  palmitoylation  using  ABE  method.  
The  reduced  signal  of  Nav1.5  AAAA  in  ‘+’  lane  (hydroxylamine  treated)  indicates  
largely  reduced  palmitoylation  of  Nav1.5  AAAA.  The  results  are  representative  of  
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H.   Palmitoylation  site  associated  with  Nav1.5  disease  mutation  
1.   Nav1.5  mutation  at  C981  is  associated  with  cardiac  arrhythmia  
disease    
Numerous  missense  mutations  in  Nav1.5  have  been  identified  in  
individuals  with  cardiac  arrhythmia.  In  a  previously  published  study,  the  missense  
mutation  C981F  was  reported  in  patient  samples  submitted  for  long  QT  
syndrome  genetic  testing(Kapplinger,  Tester  et  al.  2009)  (Figure  39A).  Because  
this  mutation  occurs  at  one  of  the  four  endogenous  palmitoylation  sites,  we  
developed  a  Nav1.5  construct  containing  this  mutation  (Nav1.5-­C981F)  and  
investigated  its  biophysical  properties  in  HEK293T  cells.  A  significant  shift  of  
steady-­state  inactivation  to  more  hyperpolarized  voltages  was  observed  when  
comparing  to  wt  Nav1.5  (Figure  39B).  No  change  in  the  rate  of  open  channel  fast  
inactivation  was  detected  (Figure  39C)  and  the  C981F  mutant  channel  did  not  
exhibit  enhanced  persistent  current  generation.  
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Figure  39.  Loss  of  cysteine  mutation  identified  from  a  patient  with  cardiac  
arrhythmia  affects  biophysical  properties  of  Nav1.5.  All  data  are  shown  as  
mean±s.e.m.  (A)  Long-­QT3  mutation  (C981F,  red)  that  can  potentially  abolish  the  
endogenous  palmitoylation  in  wild-­type  Nav1.5.  (B)  Comparison  of  voltage  
dependence  of  activation  and  steady-­state  inactivation  of  wild-­type  Nav1.5  
(black)  and  C981F  mutant  channels  (red).  (C)  Normalized  current  of  wild-­type  
Nav1.5  channel  (black)  and  Nav1.5-­C981F  (red).
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2.   Identification  of  C981  as  a  critical  site  for  Nav1.5  palmitoylation    
To  understand  if  altered  palmitoylation  contributes  to  the  shift  of  the  
inactivation  curve,  we  treated  the  Nav1.5-­C981F  transfected  cells  with  2-­Br-­
palmitate  as  in  previous  experiments.  We  found  that  2-­Br-­palmitate  treatment  
had  very  little  effect  on  Nav1.5-­C981F  channel  steady-­state  inactivation  (Figure  
40A).  To  confirm  that  the  effect  is  specifically  due  to  the  loss  of  the  cysteine  
residue  and  not  to  insertion  of  a  bulky  hydrophobic  residue,  we  examined  a  
cysteine  to  alanine  mutation  at  the  same  site.  Nav1.5-­C981A  also  exhibited  a  
hyperpolarized  steady-­state  inactivation  and  revealed  insensitivity  to  2-­Br-­
palmitate  treatment  (Figure  40B).  Moreover,  in  our  study,  both  C981F  and  C981A  
exhibited  very  similar  properties  to  the  Nav1.5-­AAAA  channel.  This  indicates  that  
the  C981  site  alone  accounts  for  the  major  palmitoylation  effect  on  Nav1.5  
steady-­state  inactivation,  and  is  likely  to  be  the  most  important  site  among  the  
four  predicted  cysteines.  To  further  confirm  the  role  of  the  C981  site  and  
investigate  the  roles  of  other  cysteine  residues,  we  also  tested  a  Nav1.5  mutant  
with  C981  intact  and  the  other  three  cysteines  mutated  to  alanines  (Nav1.5-­
AAA).  Results  with  this  mutant  channel  indicate  that  depalmitoylation  has  a  
significant  effect  on  Nav1.5-­AAA  steady-­state  inactivation  (Figure  40C).  This  
effect  was  also  observed  in  the  C1178A  mutation  (Figure  40D).  These  results  
further  validate  the  critical  and  specific  role  of  C981  palmitoylation  in  regulating  
channel  gating  properties.  
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Figure  40.  Identification  of  Nav1.5  palmitoylation  at  C981.  (A)  Nav1.5-­C981F  
channel  activation  and  steady-­state  inactivation  with  (green)  and  without  (black)  
2-­Br-­palmitate(2BP)  treatment.  (B)  Nav1.5-­C981A  voltage  dependence  of  
activation  and  steady-­state  inactivation  with  (green)  and  without  (black)  2-­Br-­
palmitate  treatment.  The  dotted  line  indicates  the  wild-­type  Nav1.5  steady-­state  
inactivation.  (C-­D)  2-­Br-­palmitate  treatment  (green)  affect  Nav1.5-­AAA  (C)  and  
Nav1.5-­C1178A  (D)  voltage  dependence  of  activation  and  steady-­state  
inactivation.    



























































































































   121  
  
Table  7.  Midpoint  voltage  of  activation  and  steady  state  inactivation  with  a  
standard  Boltzmann  distribution  fit.    
All  data  are  shown  as  mean±s.e.m.  #  indicates  p<0.05  compared  with  wild-­type  
group.  *  indicates  p<0.05  compared  with  the  corresponding  non-­treatment  group.  
The  two-­tailed,  Student's  t-­test  was  used  to  study  the  statistical  significance.  
Channel  construct   Activation   Inactivation  
   V1/2  (mV)   K  (mV)   V1/2  (mV)   K  (mV)  
Nav1.5  stable   -­33.4±0.3   7.8±0.2   -­90.4±0.6   7.1±0.5  
Nav1.5  stable  2BP   -­34.1±0.4   8.9±0.4*   -­103±0.5*   8.1±0.4*  
Nav1.5  stable  PA   -­29.9±0.4   7.7±0.4   -­83.4±0.4*   6.3±0.4  
Nav1.5  transient   -­46.3±0.4   6.9±0.3   -­90.8±0.5   7.3±0.4  
Nav1.5  transient  
2BP  
-­50.8±0.6   7.8±0.5   -­108.4±0.7*   9.7±0.6  
Nav1.5-­AAAA   -­48.2±0.4   8.1±0.4   -­103.4±0.7#   9.0±0.6  
Nav1.5-­AAAA  2BP   -­50.4±0.5   7.7±0.4   -­106.0±0.5   8.4±0.5  
Nav1.5  C981F   -­50.2±0.5   8.1±0.4   -­100.2±0.5#   6.9±0.4  
Nav1.5  C981F  2BP   -­52.6±0.4   7.3±0.4   -­100.7±0.7   8.3±0.6  
Nav1.5  C981A   -­47.8±0.7   6.7±0.6   -­100.5±0.6#   7.9±0.5  
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Nav1.5  C981A  2BP   -­43.2±0.7   8.5±0.6   -­104.8±0.9   10.3±0.8  
Nav1.5  
cardiomyocytes  








-­36.1±0.5   6.7±0.5   -­71.0±0.5*   7.3±0.5  
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I.   Supplemental  results  
1.   Identification  of  2-­Br-­palmitiate  as  a  palmitoylation  inhibitor  
To  verify  2-­Br-­palmitate  effect  on  protein  palmitoylation,  we  use  a  
palmitoylated  fluorescent  GFP  protein  which  can  indicate  its  palmitoylation  level  
by  fluorescence  visualization.  This  pCAG-­mGFP  (Addgene  plasmid  14757)  is  a  
membrane  bound  form  of  EGFP(Matsuda  and  Cepko  2007),  containing  a  
palmitoylation  sequence  of  GAP43  at  its  N-­terminus  (Figure  41).  This  protein  can  
be  expressed  on  the  surface  when  it  is  palmitoylated  and  therefore  serves  as  a  
useful  tool  to  visualize  palmitoylation  level  change  in  the  cell.          
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Figure  41.  Plasmid  map  of  cDNA  construct  of  pCAG-­mGFP.  The  copyright  of  this  
map  belongs  to  the  Addgene  Inc.  pCAG-­mGFP  encodes  a  membrane-­bound  
form  of  fluorescent  protein  (GFP)  with  a  palmitoylation  sequence  of  GAP43  at  its  
N-­terminus.  The  total  length  of  this  vector  is  about  5610  bp.  
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HEK293  cells  were  used  in  the  experiments  and  plated  in  a  glass  bottom  
dish.  The  pCAG-­mGFP  construct  was  transfected  into  the  cell  and  treated  with  2-­
Br-­palmitate  for  24  hours.  Images  of  fluorescent  cells  were  captured  using  
epifluorescence  microscope  the  next  day.  All  data  were  analyzed  using  image  
processing  software  Image  J.    
In  our  result,  we  observed  a  ring  like  structure  on  the  edge  of  each  cell  in  
control  group  and  further  analysis  of  representative  cells  indicates  peak  
fluorescence  at  cell  surface,  which  suggest  the  palmitoylation  and  surface  
expression  of  fluorescent  protein  in  the  control  group  (Figure  42  upper  panel).  
However,  in  the  2-­Br-­palmitate  treatment  group,  we  were  not  able  to  observe  the  
clear  surface  expression  of  fluorescence  protein  and  the  image  analysis  also  
indicates  the  consistent  level  of  fluorescence  throughout  the  cell  (Figure  42  
middle  and  lower  panels).  These  data  further  verify  2-­Br-­palmitate  as  a  valid  tool  
to  manipulate  palmitoylation  level  in  HEK293  cells.
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Figure  42.  2-­Br-­palmitate  affect  palmitoylation  of  mGFP  in  HEK293  cells.  Left  
column  indicates  images  recorded  from  epifluorescence  microscope.  Right  lane  
shows  the  analysis  of  fluorescence  of  representative  cells  in  each  group.  The  top  
panel  shows  the  data  from  control  group.  Middle  and  bottom  panel  shows  the  
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2.   2-­Br-­palmitiate  does  not  affect  bacterial  sodium  channel  gating  
properties  
Votage-­gated  sodium  channels  regulate  cell  electric  activity  by  mediating  
sodium  ion  conductance.  Therefore,  eukaryotic  sodium  channels  are  critical  
components  in  excitable  cells.  Recently,  a  number  of  prokaryotic  voltage-­gated  
sodium  channels  were  identified.  Among  them,  NaChBac  from  Bacillus  
halodurans,  is  the  most  studied  and  characterized  prokaryotic  sodium  channels  
(Charalambous  and  Wallace  2011).    
Eukaryotic  sodium  channels  contain  four  homologous  domains,  each  
domain  has  six  transmembrane  segments,  of  which  S1-­S4  serves  as  the  voltage  
sensor  and  S5-­S6  forms  the  pore  subdomain.  However,  unlike  eukaryotic  sodium  
channels,  NaChBac  is  one  domain  homo-­tetramer  of  six  transmembrane  helices.  
NaChBac  also  contains  a  voltage-­sensing  component  of  S1-­S4  and  a  pore-­
forming  region  by  S5-­S6.  The  positively  charged  amino  acids  on  S4  of  NaChBac  
is  the  key  residues  involved  in  channel  activation  (Chahine,  Pilote  et  al.  2004).  
The  current  kinetics  of  NaChBac,  including  activation,  inactivation  and  recovery,  
are  much  slower  compared  to  eukaryotic  sodium  channels  (Ren,  Navarro  et  al.  
2001,  Koishi,  Xu  et  al.  2004).  NaChBac  can  be  heterologous  expressed  in  
mammalian  cells  for  functional  characterization,  providing  a  useful  model  for  
studying  voltage-­gated  ion  channels.  
Protein  palmitoylation  is  unlikely  to  occur  on  NaChBac  since  the  amino  
acid  sequence  of  NaChBac  does  not  contain  any  cysteine  residues  (Figure  43  
Lower  panel).  This  provides  us  excellent  opportunity  to  study  potential  non-­
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specific  effects  of  2-­Br-­palmitate  on  voltage-­gated  sodium  channels.  Here,  we  
pretreated  the  cells  with  2-­Br-­palmitate  for  24  hours  and  compared  the  results  
from  control  group  with  treatment  group.  Our  results  indicate  that  2-­Br-­palmitate  
does  not  affect  NaChBac  voltage  dependence  of  activation  and  inactivation  
significantly  (Figure  44).  Therefore,  we  are  further  convinced  that  the  2-­Br-­
palmitate  effect  on  Nav1.5  is  due  to  inhibition  of  palmitoylation,  rather  than  other  
non-­specific  effects.  
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Figure  43.  Schematic  diagram  (upper  panel)  and  sequence  (lower  panel)  of  
voltage-­gated  bacteria  sodium  channel  structure.  S1-­S4  transmembrane  helices  
forms  the  voltage  sensor  of  NaChBac  and  S5-­S6  comprises  the  central  pore  of  
the  channel.  Bottom  panel  shows  the  amino  acid  sequence  of  NaChBac.  The  six  
transmembrane  helices  S1-­S6  and  the  central  pore  region  are  indicated.  The  
positively  charged  residues  in  the  S4  region  are  in  bold.  This  sequence  is  from  “A  
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Figure  44.  2-­Br-­palmitate  treatment  does  not  affect  Bacteria  sodium  channel  
biophysical  properties.  Black  curve  indicates  NaChBac  gating  properties  without  
treatment  and  green  curve  shows  the  NaChBac  gating  properties  with  2-­Br-­
palmiate  treatment.  Bottom  panels  shows  the  statistical  analysis  of  V50  of  voltage  
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IV.   Discussion  
A.   Overview  of  the  dissertation  research    
Palmitoylation  is  a  reversible  modification  that  regulates  various  steps  
during  protein  life  cycle,  including  trafficking,  stability  and  membrane  association.  
Palmitoylation  regulation  of  membrane  association  plays  a  role  for  many  
peripheral  membrane  proteins(Dudler  and  Gelb  1996,  Chamberlain,  Lemonidis  et  
al.  2013)  and  affects  trafficking  and  surface  expression  of  ion  channels(Jeffries,  
Geiger  et  al.  2010,  Chen,  Bi  et  al.  2013).    
Although  a  few  studies  have  indicated  that  VGSCs  in  the  brain  are  subject  
to  palmitoylation(Schmidt  and  Catterall  1987,  Bosmans,  Milescu  et  al.  2011),  it  
had  not  previously  been  determined  if  sodium  channels  from  other  excitable  
tissues  are  also  subject  to  modulation  by  palmitoylation.  More  importantly,  how  
palmitoylation  would  affect  cellular  excitability  in  any  tissue  was  unclear.  This  
study,  for  the  first  time,  utilized  both  biochemical  and  electrophysiology  
techniques  for  investigation  of  palmitoylation  in  voltage-­gated  sodium  channel  
modulation.  Our  data,  in  conjunction  with  computer  simulations,  indicate  that  
palmitoylation  can  substantially  regulate  cardiac  sodium  currents  and  that  
alterations  in  Nav1.5  palmitoylation  are  likely  to  play  important  roles  in  acquired  
and  inherited  cardiac  channelopathies.    Table  8  summarizes  key  results  of  how  
palmitoylation  regulates  Nav1.5  activities.  
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Table  8.  Summarization  of  palmitoylation  regulation  of  Nav1.5  activities.  




Density   no  change   no  change   no  change   no  change  
Fast  
Inactivation   no  change   no  change   no  change   no  change  
V1/2  












inactivation)   delay   enhance   —   —  
Slow  
Inactivation   no  change   no  change   —   —  
Recovery(slow  
inactivation)   no  change   no  change   —   —  
Persistent  
Current   no  change   enhance   no  change   no  change  
AP  activity   reduce   prolong  AP  duration   —   —  
Palmitoylation   reduce   enhance   reduce   —  
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B.   Biochemical  characterization  of  protein  palmitoylation  
In  recent  years,  the  progress  of  ion  channel  palmitoylation  research  has  
been  facilitated  by  the  development  of  new  biochemical  and  proteomics  
tools(Martin  2013,  Storck,  Serwa  et  al.  2013)  and  the  identification  of  
palmitoyltransferases  (Greaves  and  Chamberlain  2011,  Korycka,  Lach  et  al.  
2012).  The  traditional  method  of  detecting  protein  palmitoylation  involves  
metabolic  labeling  of  cells  with  radioactive  palmitate  followed  by  
immunoprecipitation  and  further  identification  of  target  proteins  by  
autoradiography  (Schmidt,  Schmidt  et  al.  1988,  Tsai,  Wynne  et  al.  2014).  This  
experiment  provides  direct  evidence  of  protein  palmitoylation(Martin  and  Cravatt  
2008).  However,  it  also  requires  extensive  utilization  of  radioactive  materials  and  
lenthy  film  exposure  for  weeks  or  even  months  depending  on  the  intensity  of  the  
palmitoylation  signal  (Yang,  Di  Vizio  et  al.  2010,  Martin,  Wang  et  al.  2011).        
The  development  of  the  non-­radioactive  ABE  assay  allows  more  rapid  detection  
of  protein  palmitoylation(Brigidi  and  Bamji  2013).  This  method  uses  
hydroxylamine  to  selectively  cleave  the  thioester  bond  at  palmitoylated  sites,  
followed  by  subsequent  labeling  of  the  newly  exposed  cysteine  thiol  with  
cysteine-­reactive  biotin  reagents.  Biotinylated  proteins  can  be  further  
immunoprecipitated  for  palmitoylation  detection  or  purified  for  mass  spectrometry  
identification  of  palmitoylation  sites(Drisdel  and  Green  2004).  This  method  
provides  higher  sensitivity  compared  to  traditional  metabolic  labeling  and  allows  
for  quantitative  estimates  of  palmitoylation.  It  is  ideal  for  measuring  the  dynamics  
of  palmitoylation  process.  However,  one  caveat  of  this  methodology  is  the  
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detection  of  all  existing  S-­acylated  proteins,  instead  of  more  specific  identification  
of  protein  palmitoylation.  This  method  also  requires  complete  block  of  all  free  
cysteines  before  thioester  cleavage,  or  false  positive  result  will  be  generated  due  
to  incomplete  alkylation  of  endogenous  hydroxylamine-­sensitive  thioesters.  
Another  commonly  used  non-­radioactive  assay  for  palmitoylation  detection  is  
click  chemistry  method(Hang,  Geutjes  et  al.  2007).  This  method  uses  the  alkyne  
fatty  acid  analog  17-­octadecynoic  acid  (17-­ODYA),  which  can  be  metabolically  
incorporated  into  endogenous  cellular  machinery  at  palmitoylation  sites(Martin  
and  Cravatt  2009).  17-­ODYA  labeled  proteins  can  be  further  linked  to  azide-­
reporter  tags  by  copper-­catalyzed  click  chemistry  and  visualized  by  in-­gel  
fluorescence  analysis(Speers  and  Cravatt  2004).  This  approach  can  also  
measure  the  rates  of  incorporation  and  dynamic  turnover  of  palmitoylation  
process  using  the  traditional  pulse-­chase  method  (Zhang,  Tsou  et  al.  2010).  One  
important  advantage  of  this  method  is  that  it  largely  reduces  the  chance  of  false  
positive  results  compared  with  ABE  assay.    
The  most  convincing  demonstration  of  palmitoylation  sites  will  be  the  
mass  spectrometry  results.  However,  it  is  often  lacking  in  most  studies  due  to  the  
complexity  of  this  lipid  modification  and  difficulties  of  resolving  the  palmitoylated  
peptides  in  mass  spectrometry  (further  discussed  in  section  E).  Therefore,  many  
studies  utilize  mutagenesis  methods  combined  with  metabolic  labeling  of  
palmitate  to  screen  potential  palmitoylation  sites.  Here  in  our  experiment,  Nav1.5  
palmitoylation  was  demonstrated  by  three  lines  of  biochemistry  evidence.  
Although  we  were  able  to  detect  Nav1.5  palmitoylation  with  tritiated  palmitate,  the  
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intensity  of  the  palmitoylation  signal  in  metabolic  labeling  experiments  was  
relatively  weak  due  to  the  low  sensitivity  of  the  method  and  the  difficulties  in  
enrichment  of  membrane  proteins.  Film  exposure  time  of  more  than  one  month  
was  required  for  clear  visualization  of  palmitoylation  signal.  Therefore,  ABE  
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C.   Alteration  of  Nav1.5  gating  properties  by  palmitoylation  
In  our  study,  palmitoylation  induced  a  small  change  in  current  
density(Figure  22).  However,  this  difference  was  not  statistically  significant,  
indicating  that  palmitoylation  has  negligible  impact  on  cell  surface  expression  of  
Nav1.5.  Instead,  our  data  demonstrate  that  Nav1.5  palmitoylation  has  profound  
impact  on  channel  availability  by  regulating  the  voltage-­dependence  of  steady-­
state  inactivation  in  both  HEK293  cells  (Figure  30)  and  cardiomyocytes  (Figure  
26).  Nav1.5  inactivation  was  largely  enhanced  in  2-­Br-­palmiate  treatment  group,  
narrowing  the  membrane  potential  range  of  window  currents.  On  the  contrary,  
Nav1.5  inactivation  was  significantly  delayed  with  palmitic  acid  treatment,  
increasing  the  voltage  range  of  window  currents.  We  also  observed  an  elevated  
persistent  sodium  current  with  palmitic  acid  treatment,  which,  together  with  the  
alteration  in  Nav1.5  inactivation,  could  potentially  lead  to  the  reactivation  of  
Nav1.5  and  enhancement  of  sodium  conductance  during  action  potential  phase  
3.  The  opposite  direction  of  changes  in  sodium  channel  gating  properties  
between  these  two  treatment  groups  suggests  that  palmitoylation  level  can  
dynamically  regulate  Nav1.5  functions  by  mediating  channel  inactivation.  Based  
on  the  relative  magnitude  of  the  shifts  induced  by  palmitic  acid  (+6  mV)  and  2-­Br-­
palmitate  (-­20  mV)  compared  to  control  experiments,  these  data  could  be  an  
indication  that  as  many  as  two-­thirds  of  the  channels  are  palmitoylated  under  our  
control  conditions.  However,  several  studies  have  identified  crosstalk  between  
palmitoylation  and  other  post-­translational  modifications  in  ion  channel  
proteins(Pickering,  Taverna  et  al.  1995,  Tian,  Jeffries  et  al.  2008,  Hayashi,  
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Thomas  et  al.  2009,  Zhou,  Wulfsen  et  al.  2012)  and  it  is  therefore  unclear  if  all  
Nav1.5  channels  were  palmitoylated  in  our  experiments.  On  the  other  hand,  if  a  
substantial  fraction  of  channels  remained  un-­palmitoylated  after  treatment  with  
excess  palmitate,  one  would  expect  to  see  either  a  biphasic  voltage-­dependence  
of  inactivation  curve,  result  in  a  large  variance  or  a  curve  with  a  shallower  slope.  
These  would  be  consistent  with  a  mixed  population  of  channels,  but  neither  was  
observed.  In  addition,  the  hyperpolarized  shift  of  inactivation  curve  of  Nav1.5-­
AAAA  is  similar  to  that  obtained  with  2-­Br-­palmitate  treatment,  indicating  that  we  
are  able  to  obtain  near  complete  removal  of  palmitoylation.  Regardless,  our  data  
show  that  palmitoylation  can  modify  the  voltage-­dependence  of  Nav1.5  
inactivation  by  20  to  25  mV,  suggesting  a  remarkable  effect  on  bi-­directional  
regulation  of  palmitoylation.  
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D.   Alteration  of  cardiomyocyte  excitability  by  palmitoylation  
Our  data  indicate  that  palmitoylation  of  Nav1.5  has  a  pronounced  impact  
on  cardiomyocyte  excitability.  Specifically,  in  our  experiment,  inhibiting  
palmitoylation  greatly  reduced  myocyte  excitability.  The  treatment  of  2-­Br-­
palmiate  abolished  beating  cells  and  no  action  potential  (spontaneously  or  
stimulated)  was  generated.  Even  though  myocytes  from  2-­Br-­palmiate  group  
remained  ‘inexcitable’  in  our  experiment  settings,  it  is  still  possible  that  prolonged  
hypoperolarization  by  injecting  negative  current  may  restore  the  cardiomyocyte  
excitability  in  2-­Br-­palmitate  treatment  group.  In  contrast,  enhancing  
palmitoylation  increased  APD  and  induced  aberrant  action  potential  firing.  
Though  our  experimental  results  illustrate  the  changes  in  cardiomyocyte  
excitability,  we  are  not  able  to  rule  out  the  possibility  that  other  electrophysiologic  
properties,  for  example,  automaticity  was  changed  as  well.  Due  to  the  shift  of  
voltage-­dependence  of  activation  and  inactivation,  it  is  likely  that  the  alteration  in  
window  currents  might  also  change  the  automaticity.  In  addition  to  that,  due  to  
the  lack  of  information  of  the  substrate  specificity  of  palmitoytransferase  in  
cardiaomyocytes,  we  cannot  rule  out  the  possibility  that  palmitoylation  
modulation  could  also  affect  many  proteins  other  than  sodium  channels.  While  
multiple  cardiac  proteins  involved  in  the  cardiac  action  potential  might  be  
palmitoylated,  our  computer  simulations  indicate  that  changes  in  Nav1.5  gating  
due  to  palmitoylation  are  sufficient  to  cause  the  excitability  changes  that  we  
observed  in  myocytes.  Furthermore,  the  C981F  mutation  provides  additional  
evidence  that  alteration  of  Nav1.5  palmitoylation  is  likely  to  impact  cardiac  action  
   139  
potentials  and  contribute  to  arrhythmogenesis.  This  mutation  was  identified  in  the  
genomic  DNA  sample  of  a  patient  referred  for  long-­QT  syndrome  clinical  genetic  
testing(Kapplinger,  Tester  et  al.  2009).  In  a  patient  cohort  of  2500  unrelated  
cases,  110  distinct  mutations  were  identified  in  SCN5A  that  were  absent  in  
the  >2,600  control  alleles.  Although  most  of  the  patients  were  believed  to  have  
been  referred  due  to  a  long-­QT  phenotype,  some  were  referred  because  they  
had  Brugada  syndrome  phenotypes  (Kapplinger,  Tester  et  al.  2009).  Based  on  
the  biophysical  analysis  of  C981F  mutation,  we  predict  that  the  patient  with  the  
C981F  mutation  more  likely  had  a  Brugada  or  overlapping  syndrome  phenotype,  
although  unfortunately  definitive  phenotypic  data  was  not  available  in  the  study  
that  reported  the  C981F  mutation(Kapplinger,  Tester  et  al.  2009).    
Interestingly,  we  also  identified  four  long-­QT3  mutations  in  the  literature  (R34C,  
R1175C,  F1473C,  R1644C)  that  our  analysis  predicts  could  add  an  additional  
palmitoylation  site  on  Nav1.5,  suggesting  that  enhanced  palmitoylation  may  
contribute  to  the  biophysical  alterations  induced  by  some  long-­QT  mutations.  In  
contrast  to  C981F  effects,  Bankston  and  colleagues  reported  that  the  F1473C  
Nav1.5  mutation,  a  long-­QT  mutation  associated  with  a  severe  clinical  
phenotype,  had  similar  biophysical  consequences  as  those  we  observed  with  
palmitic  acid  treatment(Bankston,  Yue  et  al.  2007).  The  F1473C  mutation  shifted  
the  midpoint  of  Nav1.5  inactivation  in  the  depolarizing  direction  by  9  mV  and  
increased  persistent  (late)  currents  to  ~0.6%  of  the  peak  current.  Furthermore,  
they  used  a  computer  model  of  a  ventricular  myocyte  to  show  that  the  combined  
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shift  in  steady-­state  inactivation  and  increase  in  persistent  current  amplitude  is  
sufficient  to  double  the  duration  of  the  ventricular  action  potential.    
All  together  these  data  suggest  that  while  depalmitoylation  of  a  key  
Nav1.5  cysteine  can  result  in  reduced  cardiac  excitability  similar  to  that  observed  
with  Brugada  syndrome,  excessive  palmitoylation  of  Nav1.5  can  lead  to  
enhanced  cardiac  activity  similar  to  that  observed  with  long  QT-­syndrome  
mutations.  
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E.   Potential  endogenous  palmitoylation  sites  
Palmitoylation  has  been  identified  on  various  types  of  proteins,  however,  
there  is  no  clear  consensus  sequence  of  palmitoylation  among  substrate  
proteins.  Previous  studies  show  that  cysteines  that  are  close  to  transmembrane  
domains  are  preferred  sites  for  protein  palmitoylation,  probably  because  the  
accessibility  to  membrane  associated  palmitoyltransferase  (Bijlmakers  and  
Marsh  2003).  Apart  from  their  distance  to  transmembrane  domains,  
palmitoylation  sites  are  often  close  to  myristoylation  and  prenylation  sites  and/or  
surrounded  by  hydrophobic  residues  (Salaun,  Greaves  et  al.  2010).    
The  lack  of  a  precise  consensus  sequence  and  the  diverse  features  of  the  
amino  acids  found  to  influence  palmitoylation  makes  it  challenging  to  predict  the  
potential  palmitoylation  site.  The  bioinformatics  tool  CSS-­Palm  3.0  utilizes  a  
clustering  and  scoring  algorithm  by  comparing  the  surrounding  amino  acid  
sequence  similarity  with  experimentally  determined  palmitoylation  sites.  
Four  endogenous  palmitoylation  sites  that  were  likely  to  regulate  Nav1.5  
palmitoylation  were  identified  using  this  prediction  algorithm.  Moreover,  we  also  
examined  the  location  of  these  four  residues  and  they  are  all  found  in  the  second  
major  cytoplasmic  loop  where  palmitoylation  is  likely  to  happen  (Figure  36).  
Mutation  of  these  four  cysteines  to  alanines  had  essentially  the  same  effect  on  
steady-­state  inactivation  as  2-­Br-­palmitate  treatment  did  on  wt  Nav1.5,  and  the  
Nav1.5-­AAAA  channels  were  insensitive  to  modulation  by  2-­Br-­palmitate  
treatment  (Figure  37),  indicating  that  one  or  more  of  these  cysteines  are  
responsible  for  the  change  in  inactivation  observed  with  wild  type  Nav1.5  
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depalmitoylation.  The  Nav1.5  C981F  and  C981A  channels  had  almost  the  same  
inactivation  properties  as  the  Nav1.5-­AAAA  channel  (Figure  40),  indicating  that  
C981  is  likely  to  be  the  crucial  site  at  which  palmitoylation  modulates  inactivation  
of  Nav1.5.  However,  the  detailed  mechanism  of  how  palmitoylation  of  C981  
impacts  the  voltage-­dependence  of  steady-­state  inactivation  is  still  unknown.  We  
noticed  that  all  of  the  sites  that  are  implicated  in  Nav1.5,  as  well  as  the  
endogenous  palmitoylation  sites  predicted  in  Nav1.2  to  modulate  steady-­state  
inactivation,  are  located  in  the  cytoplasmic  linker  between  domains  II  and  III.  One  
possibility  is  that  by  increasing  association  of  this  linker  to  the  membrane,  
palmitoylation  may  alter  the  movement  of  the  domain  III  voltage-­sensor,  which  is  
important  for  channel  inactivation(Cha,  Ruben  et  al.  1999).  Although  our  data  
clearly  indicate  that  C981  palmitoylation  is  crucial  to  the  gating  changes  that  we  
observed,  we  were  unable  to  generate  a  stable  cell  line  containing  only  a  C981  
mutant  channel  for  further  biochemical  analysis.  Therefore,  we  cannot  rule  out  
the  possibility  that  one  or  more  of  the  other  three  predicted  sites  are  
palmitoylated  and  that  this  might  modulate  other  properties  of  Nav1.5  in  cardiac  
myocytes.    
Furthermore,  the  mass  spectrometry(MS)  experiments  were  attempted  to  
better  identify  endogenous  palmitoylation  sites.  Unfortunately,  due  to  the  relative  
large  size  of  sodium  channel  protein  and  the  instability  of  palmitoylation  sites  
under  reducing  conditions,  we  were  not  able  to  achieve  high  coverage  of  the  
sodium  channel  and  identify  protein  palmitoylation  at  any  cysteine  sites  (Figure  
45).  The  standard  protocol  involves  reducing  disulfides  and  alkylating  free-­
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cysteine  side  chains  with  iodoacetamide.  The  reducing  agent  (DTT)  may  remove  
some  of  the  palmitoylation  and  leave  the  sites  alkylated  with  iodoacetamide.  
Also,  palmitoylated peptides are generally very challenging to resolve in Liquid 
chromatography (LC) and LC-MS due to the dramatic difference in 
hydrophobicity after lipid modification (Ji, Leymarie et al. 2013).  On  account  of  
the  above  mentioned  difficulties,  further  identification  of  precise  location  of  
palmitoylation  sites  with  mass  spectrometry  could  not  be  accomplished  in  this  
project.  
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Figure	  45.	  Identified	  peptides	  with	  Mass	  Spectrometry	  experiment.	  The	  red	  color	  
indicates	  identified	  peptides,	  which	  covers	  6%	  of	  the	  total	  sequence.	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F.   Future  directions  
Our  study  demonstrates  that  palmitoylation  changes  have  profound  impact  
on  cardiac  myocyte  excitability.  However,  we  do  not  yet  understand  the  
molecular  mechanism  behind  this  process  and  how  that  may  alter  therapeutic  
treatment  of  arrhythmia  diseases.  To  further  explore  how  palmitoylation  alters  
pharmacological  response  to  antiarrhythmic  drugs,  we  performed  a  series  of  
preliminary  studies  with  Lidocaine,  a  class  Ib  sodium  channel  blocker  that  
reduces  sodium  current  and  shortens  action  potential  duration(Bean,  Cohen  et  
al.  1983).  Our  data  demonstrates  that  the  inhibition  effect  of  lidocaine  on  sodium  
current  was  significantly  enhanced  after  2-­Br-­palmitate  treatment.  Since  lidocaine  
preferentially  binds  open  and  inactivated  sodium  channels(Matsubara,  Clarkson  
et  al.  1987),  one  possible  explanation  is  that  enhanced  inactivation  of  Nav1.5  
after  2-­Br-­palmitate  treatment  could  facilitate  lidocaine  binding,  thus  lead  to  
increased  sodium  channel  blockage.  On  the  contrary,  lidocaine  blockage  of  
sodium  current  was  significantly  reduced  with  palmitic  acid  treatment,  probably  at  
a  result  of  delayed  sodium  channel  inactivation  after  palmitic  acid  treatment.  
Since  different  types  of  antiarrhythmic  drugs  affect  distinct  aspects  of  sodium  
channel  gating,  they  may  respond  differently  upon  altered  palmitoylation  level.  
Therefore,  more  experiments  comparing  different  classes  of  antiarrhythmic  drugs  
need  to  be  done  to  further  explore  the  differential  regulation  on  channel  
pharmacological  effects  by  palmitoylation.  Overall,  our  preliminary  data  supports  
the  idea  that  palmitoylation  may  have  substantial  impact  on  pharmacological  
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response  to  antiarrhythmic  drugs  and  may  provide  guidance  on  the  therapeutic  
management  of  cardiac  arrhythmia  diseases.    
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G.   Summary  and  conclusion  
      This  dissertation  research  provides  important  insights  into  how  
palmitoylation  regulates  cardiac  sodium  channel  function  and  myocyte  
excitability.  In  this  study,  we  demonstrate  that  Nav1.5  is  palmitoylated  in  both  a  
heterologous  expression  system  and  in  native  cardiac  tissue,  using  both  
biochemical  and  electrophysiological  assays.  Our  data  show  that  palmitoylation  
of  Nav1.5  can  substantially  modulate  the  inactivation  properties  of  cardiac  
sodium  currents  and  lead  to  bidirectional  alterations  in  cardiac  excitability.  We  
also  identify  potential  palmitoylation  sites  regulating  this  process(Pei,  Xiao  et  al.  
2016).    
The  existence  of  disease  related  mutations  that  alter  potential  
palmitoylation  sites  illustrates  how  the  potential  loss  of  palmitoylation  at  this  
crucial  residue  alters  channel  inactivation  and  dysregulates  myocyte  excitability  
to  contribute  to  cardiac  disease.  Thus  the  modulation  of  cardiac  sodium  channel  
palmitoylation  is  likely  to  be  an  unrevealed  mechanism  of  cardiac  arrhythmia  
generation.  A  previous  study  indicates  that  palmitoylation  of  cardiac  proteins  
increases  during  reoxygenation  of  anoxic  cardiac  tissue(Lin,  Fine  et  al.  2013),  
and  thus  enhanced  palmitoylation  of  cardiac  sodium  channels  could  contribute  to  
reperfusion  induced  arrhythmias.  Evidence  indicates  that  palmitoylation  can  also  
be  altered  by  diet,  stress  and  redox  signaling(Burgoyne,  Haeussler  et  al.  2012).  
Although  the  vast  majority  of  long-­QT3  and  Brugada  syndrome  mutations  may  
not  directly  alter  Nav1.5  palmitoylation,  increased  palmitoylation  of  Nav1.5  is  
predicted  to  enhance  EADs  and  arrhythmias  in  patients  with  long-­QT3  and  
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reduced  palmitoylation  of  Nav1.5  is  expected  to  exacerbate  symptoms  in  patients  
with  Brugada  syndrome;;  thus  regulation  of  Nav1.5  activity  by  palmitoylation  could  
be  important  in  multiple  cardiac  pathophysiological  conditions.  Brain  sodium  
channel  activity  is  also  likely  to  be  regulated  by  palmitoylation(Kang,  Wan  et  al.  
2008)  and  altered  palmitoylation  has  been  implicated  in  a  number  of  neurological  
disorders(Young,  Butland  et  al.  2012).  Overall,  alterations  in  palmitoylation  of  
voltage-­gated  sodium  channels  are  likely  to  have  profound  effects  on  cellular  
excitability  in  a  variety  of  tissues  and  pathophysiological  conditions.
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Molecular  Biology:  PCR;;  DNA  extraction  and  purification;;  site-­directed  
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Post-­translational  modification  of  sodium  channel  and  its  association  with  cardiac  
diseases.    
Novel  cardiac  sodium  channel  post-­translational  lipid  modification,  palmitoylation,  
was  identified  and  validated  using  acyl-­biotin  exchange  assay  (ABE)  and  
electrophysiology  method.  The  palmitoylation  sites  were  studied  using  
bioinformatics  prediction  tool  and  site-­directed  mutagenesis.  Biophysical  
properties  change  caused  by  channel  palmitoylation  was  examined  using  voltage  
clamp  and  current  clamp  on  both  HEK293  cells  and  cultured  cardiomyocytes.  
Anti-­arrhythmia  drugs  were  applied  to  study  how  palmitoylation  can  change  the  
pharmacological  properties  of  the  cardiac  sodium  channel.    
  
Selective  modulation  of  gating  charge  mutations  on  cardiac  sodium  channel  and  
contribution  of  gating  pore  currents  to  cardiac  arrhythmia  disease.  
Characterization  of  gating  pore  currents  generated  by  gating  charge  mutations  
located  in  the  voltage  sensor  domain.  Study  the  LQT3  mutations  that  neutralize  
gating  charges  and  the  association  of  generated  gating  pore  currents  with  
cardiac  arrhythmia  disease.    
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student  
Tamoxifen  and  its  metabolite  as  potent  and  selective  inhibitors  of  aromatase  
(CYP19)  and  their  potential  use  as  a  therapeutic  drug.    
Characterization  the  inhibition  effect  of  tamoxifen  and  its  metabolites  on  CYP450  
enzymes  using  microsomal  incubations.  High  throughput  characterization  of  the  
activity  of  recombinant  human  CYP  isoform  using  enzyme  activity  assay.  
Quantification  of  the  testosterone  conversion  to  estradiol  and  of  methadone  
conversion  to  EDDP  using  HPLC  
  
